Protocol Number: ADCT -301-201 
 
Official Title:  A Phase 2, Open- Label, Single -Arm Study to Evaluate the Efficacy and Safety of 
Camidanlumab Tesirine (ADCT -301) in Patients with Relapsed or  Refractory Hodgkin Lymphoma  
 
Study ID: [REMOVED]  
 
Document Date: 16  February  2022  
ADC Therapeutics  Camidanlumab tesirine (ADCT -301) 
Final ADCT -301-201 Clinical Protocol  Protocol Amendment 5 
Date of Protocol  Amendment 5: 16 February 2022  Page 3 of 87 Declaration of Investigator  
I have read and understood all sections of the protocol entitled: “ A Phase 2, Open-Label, 
Single- Arm Study to Evaluate the Efficacy and Safety of Camidanlumab Tesirine (ADCT -301) 
in Patients with Relapsed or Refractory Hodgkin Lymphoma ” and the accompanying 
Investigator ’s Brochure (IB) . 
I agree to supervise all aspects of the protocol and to conduct the clinical investigation in 
accordance with the Protocol  Amendment 5, dated  16 February 2022, the current version of 
International Co uncil for Harmonisation (ICH) harmonised tripartite guideline 
E6: Good Clinical Practice, and all applicable governmental regulations. I will not make 
changes to the protocol before consulting with ADC Therapeutics or implement protocol changes without independent ethics committee approval except to eliminate an immediate risk 
to patient s. I agree to administer  the study drug  only to patients under my personal supervision 
or the supervision of a sub-Investigator. 
I will not supply the study  drug to any person not authorized to receive it. Confidentiality will 
be protected . Patient  identity will not be disclosed to third parties or appear in any study reports 
or publications. I will not disclose information regarding this clinical investigation or publish results of the 
investigation without authorization from ADC Therapeutics SA. 
 
    
   
Signature of Principal Investigator   Date  
 
    
   
Printed Name of Principal Investigator   
 
ADC Therapeutics  Camidanlumab tesirine (ADCT -301) 
Final ADCT -301-201 Clinical Protocol  Protocol Amendment 5 
Date of Protocol  Amendment 5: 16 February 2022  Page 4 of 87 Table of Contents  
Title Page  .................................................................................................................................. 1  
Protocol Approval – Sponsor Signatory ................................................................................... 2  
Declaration of Investigator  ....................................................................................................... 3  
Table of Contents ...................................................................................................................... 4  
List of Tables  ............................................................................................................................. 8  
List of Figures ........................................................................................................................... 8  
List of Abbreviations ................................................................................................................. 9  
Summary of Changes .............................................................................................................. 12  
List of Prior Protocol Versions  ................................................................................................ 13  
Protocol Synopsis.................................................................................................................... 14  
Schedule of Events .................................................................................................................. 21  
1 Introduction and Background ......................................................................................... 24  
1.1 Targeting CD25-positive Tumor Cells in Hodgkin Lymphoma .....................................24  
1.2 Description of Investigational Study Drug .....................................................................24  
1.3 Safety and Efficacy of Camidanlumab Tesirine in Phase 1 Study, ADCT -301-001 ......25  
2 Study Rationale .............................................................................................................. 27  
2.1 Rationale for Study Design ............................................................................................27  
2.2 Rationale for Dose Selection  ..........................................................................................27  
3 Study Objectives and Endpoints ..................................................................................... 29  
4 Study Design .................................................................................................................. 31  
4.1 Overview ........................................................................................................................31  
4.2 Study Periods ..................................................................................................................31  
4.2.1  Screening Period .........................................................................................................31  
4.2.2  Treatment Period  .........................................................................................................31  
4.2.3  End of Treatment  ........................................................................................................31  
4.2.4  Follow-up Period ........................................................................................................32  
4.2.5  End of Study ...............................................................................................................32  
4.3 Study Stopping Rules .....................................................................................................32  
5 Patient Population  ........................................................................................................... 33  
5.1 Inclusion Criteria  ............................................................................................................33  
5.2 Exclus ion Criteria  ...........................................................................................................34  
5.3 Screening Failures  ..........................................................................................................36  
5.4 Re-screening Procedures ................................................................................................36  
ADC Therapeutics  Camidanlumab tesirine (ADCT -301) 
Final ADCT -301-201 Clinical Protocol  Protocol Amendment 5 
Date of Protocol  Amendment 5: 16 February 2022  Page 5 of 87 5.5 Discontinuation ..............................................................................................................36  
5.5.1  Discontinuation from Study Drug ..............................................................................36  
5.5.2  Discontinuation from the Study ..................................................................................37  
5.5.3  Loss to Follow-up .......................................................................................................37  
5.6 Patient Replacements .....................................................................................................37  
6 Treatment  ........................................................................................................................ 38  
6.1 Study Drug .....................................................................................................................38  
6.2 Management of Clinical Supplies ..................................................................................38  
6.2.1  Packaging and Storage ................................................................................................38  
6.2.2  Preparation and Administration  ..................................................................................38  
6.2.3  Accountability .............................................................................................................39  
6.3 Camidanlumab Tesirine Dosing  .....................................................................................39  
6.4 Dose Delays and Modifications  .....................................................................................39  
6.4.1  Guidelines for Dose Modification: General ...............................................................40  
6.4.2  Guidelines for Dose Modification: Specific Non- hematologic Toxicities  .................41  
6.4.3  Guidelines for Dose Modification: Specific Hematologic Toxicities  .........................43  
6.4.4  Guidelines for Dose Modification: Specific Neurologic Toxicities ...........................43  
6.4.5  Guidelines for Dose Modification: Specific Skin Toxicities  ......................................44  
6.5 Overdose Management  ...................................................................................................47  
6.6 Treatment Compliance  ...................................................................................................47  
6.7 Premedication and Supportive Care ...............................................................................47  
6.7.1  Premedication  .............................................................................................................47  
6.7.2  Treatment of Edema and Pleural Effusion  ..................................................................47  
6.7.3  Treatment and Prophylaxis of Infusion- Related Hypersensitivity Reactions .............48  
6.7.4  Consideration for Skin Toxicity ..................................................................................48  
6.7.5  Diagnostic, Work-up, and Management of Polyradiculopathy/ Guillain- Barré 
Syndrome ....................................................................................................................49  
6.7.6  Other Supportive Care ................................................................................................50  
6.8 Concomitant Medications and Procedures  .....................................................................50  
6.8.1  Permitted During Study  ..............................................................................................50  
6.8.2  Prohibited During Study .............................................................................................50  
7 Study Assessments and Procedures  ................................................................................ 51  
7.1 Informed Consent  ...........................................................................................................51  
7.2 Demographics and Baseline Characteristics  ..................................................................51  
7.3 Efficacy Assessments .....................................................................................................51  
7.4 Safety Assessments  ........................................................................................................52  
7.4.1  Physical Examination  .................................................................................................52  
7.4.2  ECOG Performance Status  .........................................................................................53  
ADC Therapeutics  Camidanlumab tesirine (ADCT -301) 
Final ADCT -301-201 Clinical Protocol  Protocol Amendment 5 
Date of Protocol  Amendment 5: 16 February 2022  Page 6 of 87 7.4.3  Height and Weight  ......................................................................................................53  
7.4.4  Vital Signs  ...................................................................................................................53  
7.4.5  Laboratory  Tests  .........................................................................................................53  
7.4.6  Pregnancy Test  ............................................................................................................55  
7.4.7  ECG  ............................................................................................................................55  
7.5 Pharmacokinetics, Pharmacodynamics, and Immunogenicity .......................................57  
7.5.1  Pharmacokinetics ........................................................................................................58  
7.5.2  Immunogenicity ..........................................................................................................59  
7.5.3  Biomar kers ..................................................................................................................59  
7.5.3.1  Blood Samples for Biomarkers ............................................................................. 59  
7.5.3.2  Tumor Tissue for Biomarkers ............................................................................... 60  
7.6 Health -Related Quality of Life (HRQoL) Questionnaires  .............................................61  
7.6.1  EuroQoL-5 Dimensions- 5 Levels (EQ -5D- 5L) ..........................................................61  
7.6.2  Functional Assessment of Cancer Therapy - Lymp homa (FACT -Lym)  .....................61  
8 Adverse Events ............................................................................................................... 62  
8.1 Definition of Adverse Events, Serious Adverse Events, and Adverse Events of 
Special Interest  ...............................................................................................................62  
8.1.1  Adverse Events of Special Interest  .............................................................................62  
8.2 Eliciting and Reporting Adverse Events/Adverse Events of Special Interest/Serious Adve rse Events  ...............................................................................................................63
 
8.3 Assessment of Severity  ..................................................................................................64  
8.4 Assessment of Causality  .................................................................................................65  
8.5 Regulatory Reporting  .....................................................................................................65  
8.6 Pregnancy Reporting  ......................................................................................................65  
8.7 Independent Data and Safety Monitoring Board ............................................................66  
9 Statistical Considerations  ............................................................................................... 67  
9.1 Sample Size Calculation  .................................................................................................67  
9.2 Analysis Populations ......................................................................................................67  
9.3 Interim Analysis  .............................................................................................................67  
9.4 Final Analysis  .................................................................................................................67  
9.5 Demographics and Baseline Characteristics  ..................................................................68  
9.6 Exposure to Treatments  ..................................................................................................68  
9.7 Efficacy Analyses  ...........................................................................................................68  
9.7.1  Overall Response Rate  ................................................................................................68  
9.7.2  Duration of Response .................................................................................................68  
9.7.3  Complete Response Rate ............................................................................................69  
9.7.4  Relapse-free Survival ..................................................................................................69  
9.7.5  Progression-free Survival ...........................................................................................69  
ADC Therapeutics  Camidanlumab tesirine (ADCT -301) 
Final ADCT -301-201 Clinical Protocol  Protocol Amendment 5 
Date of Protocol  Amendment 5: 16 February 2022  Page 7 of 87 9.7.6  Overall Survival ..........................................................................................................69  
9.7.7  Patients Receiving Transplant  .....................................................................................69  
9.8 Safety Analyses  ..............................................................................................................69  
9.8.1  Adverse Events ...........................................................................................................70  
9.8.2  Clinical Laboratory Results  ........................................................................................70  
9.8.3  Additional Safety Assessments  ...................................................................................70  
9.9 Pharmacokinetic Analyses  ..............................................................................................70  
9.10  Immunogenicity Analyses  ..............................................................................................71  
9.11  Exploratory Analyses  .....................................................................................................72  
10 Data Management and Quality Assurance  ..................................................................... 73  
11 Ethical, Regulatory, and Study Management Considerations ........................................ 74  
11.1  Regulatory and Ethical Conduct of the Study ................................................................74  
11.2  Independent Ethics Committee or Institutional Review Board  ......................................74  
11.3  Patient Information and Consent ....................................................................................74  
11.4  Confidentiality  ................................................................................................................75  
11.5  Financial Disclosure and Obligations ............................................................................75  
11.6  Study Conduct ................................................................................................................75  
11.7  Protocol Amendments  ....................................................................................................75  
11.8  Monitoring of the Study .................................................................................................76  
11.9  Records Retention  ..........................................................................................................76  
11.10  Publications  ....................................................................................................................76  
12 Reference List  ................................................................................................................. 77  
13 Appendices ..................................................................................................................... 80  
13.1  Appendix: Eastern Cooperative Oncology Group Performance Status .........................80  
13.2  Appendix: Clinical Case Definitions: Level 1 of Diagnostic Certainty for Guillain -
Barré Syndrome (GBS)  ..................................................................................................81  
13.3  Appendix: Guillain–Barré Syndrome Disability S cale ..................................................82  
13.4  Appendix: Response Assessment of Hodgkin and Non-Hodgkin Lymphoma 
(Lugano Classification) ..................................................................................................83  
13.5  Appendix: Management of Specific Autoimmune Toxicities: Hyperthyroidism, Hypothyroidism, and Hepatitis ......................................................................................86
 
  
ADC Therapeutics  Camidanlumab tesirine (ADCT -301) 
Final ADCT -301-201 Clinical Protocol  Protocol Amendment 5 
Date of Protocol  Amendment 5: 16 February 2022  Page 8 of 87 List of Tables  
Table  1 Schedule of Events .............................................................................................. 21  
Table  2 Study Objectives and Endpoints .......................................................................... 29  
Table  3 Schedule for Triplicate ECG Collection  .............................................................. 56  
Table  4 Sampling Schedule for PK and ADA .................................................................. 58  
Table  5 Sampling Schedule for Soluble Biomarkers ........................................................ 60  
Table  6 Definition of Severity Grades for CTCAE  .......................................................... 65  
Table  7 Number of Responses Needed to Have 95% CI Low Bound of ORR >35% ...... 68  
 
 
List of Figures  
Figure 1  Schematic Representation and Chemical Structure of Camidanlumab Tesirine  . 25  
Figure 2  Preferred Sequence for Triplicate Electrocardiogram (ECG), Vital Signs, and Pharmacokinetic (PK) Sample Assessments at End of Infusion (EOI)  ............... 57
 
Figure 3  Anti-drug Antibody Tiered Immunogenicity Testing Strategy  ............................ 71  
  
ADC Therapeutics  Camidanlumab tesirine (ADCT -301) 
Final ADCT -301-201 Clinical Protocol  Protocol Amendment 5 
Date of Protocol  Amendment 5: 16 February 2022  Page 9 of 87 List of Abbreviations  
Abbreviation  Definition  
ADA  anti-drug antibody  
ADC  antibody -drug conjugate  
AE adverse event  
AESI  adverse event of special interest  
AI accumulation index  
ALP  alkaline phosphatase  
ALT alanine aminotransferase  
ANC  absolute neutrophil count  
aPTT  activated partial thromboplastin time  
ASCO  American Society of Clinical Oncology  
AST  aspartate aminotransferase  
AUC inf area under the concentration -time curve from time zero to infinity  
AUC last area under the concentration -time curve from time zero to the last 
quantifiable concentration  
AUC tau area under the concentration -time curve from time zero to the end of the 
dosing interval  
BID twice daily  
β-HCG  human  chorionic gonadotropin  
BOR  best overall response  
BP blood pressure  
C1D1  Cycle 1, Day 1  
CD cluster of differentiation  
CFR  Code of Federal Regulations  
cHL classical Hodgkin  lymphoma  
CI confidence interval  
CL clearance  
Cmax maximum concentration  
CMV  cytomegalovirus  
CR complete response  
CRO  contract research organization  
CSR  clinical study report  
CT computed tomography  
CTCAE  Common Terminology Criteria for Adverse Events  
DNA  deoxyribonucleic acid  
DOR  duration of response  
EBV  Epstein -Barr virus  
ECG  electrocardiogram(s)  
ECOG  Eastern Cooperative Oncology Group  
eCRF  electronic case report form  
EDC  electronic data capture  
EOI end of infusion  
EOS  end of study  
EOT  end of treatment  
ADC Therapeutics  Camidanlumab tesirine (ADCT -301) 
Final ADCT -301-201 Clinical Protocol  Protocol Amendment 5 
Date of Protocol  Amendment 5: 16 February 2022  Page 10 of 87 Abbreviation  Definition  
EQ-5D-5L EuroQo L–5 Dimensions –5 Levels  
FACT -Lym Functional Assessment of Cancer Therapy -Lymphoma  
FDA  Food and Drug Administration  
FFPE  formalin -fixed paraffin -embedded  
FIH first-in-human  
FSH follicle stimulating hormone  
FT3 free t riiodothyronine  
FT4 free thyroxine  
G-CSF granulocyte colony -stimulating factor  
GBS  Guillain -Barré syndrome  
GCP  Good Clinical Practice  
GGT  gamma glutamyl transferase  
GVHD  graft -versus -host disease  
HBV  hepatitis B virus  
HCV  hepatitis C virus  
HIV human immunodeficiency virus  
HL Hodgkin lymphoma  
HR heart rate  
HRQoL  health -related quality of life  
HSCT  hematopoietic stem cell transplant  
HSV1  herpes simplex virus 1  
HSV2  herpes simplex virus 2  
IB Investigator ’s Brochure  
ICF informed consent form  
ICH International Council for Harmonisation  
iDSMB  independent Data and Safety Monitoring Board  
IEC independent ethics committee  
IL interleukin  
IFNγ interferon gamma  
INR international normalized ratio  
IRB institutional review board  
IV intravenous  
IVIg  intravenous immunoglobulin  
MedDRA  Medical Dictionary for Regulatory Activities  
MRI  magnetic resonance imaging  
MTD  maximum tolerated dose  
ORR  overall response rate  
OS overall survival  
PBD  pyrrolobenzodiazepine  
PCR  polymerase chain reaction  
PD progressive disease  
PET-CT positron emission tomography -computed tomography  
PFS progression -free survival  
PK pharmacokinetic(s)  
PLEX  plasma exchange  
ADC Therapeutics  Camidanlumab tesirine (ADCT -301) 
Final ADCT -301-201 Clinical Protocol  Protocol Amendment 5 
Date of Protocol  Amendment 5: 16 February 2022  Page 11 of 87 Abbreviation  Definition  
PR partial response  
Q3W  every 3 weeks  
QoL quality of life  
QT measure between Q wave and T wave  in the electrocardiogram  
QTcB  Bazett correction of the QT measure  
QTcF  Fridericia correction of the QT measure  
RBC  red blood cell  
RFS relapse -free survival  
SAE  serious adverse event  
SAP statistical analysis plan  
SARS -CoV-2 respiratory syndrome coronavirus 2  
sCD25  soluble CD25  
SD stable disease  
SoC standard of care  
SoE schedule of events  
SUSAR  suspected unexpected serious adverse reaction  
TANT  tumor -associated non -tumor cells  
TEAE  treatment -emergent adverse event(s)  
TIL tumor infiltrating lymphocytes  
TLS tumor lysis syndrome  
Thalf apparent  terminal elimination half -life 
Tmax time to maximum concentration  
TNF α tumor necrosis factor alpha  
TSH  thyroid -stimulating hormone  
ULN  upper limit of normal  
VA S visual analog scale  
Vss volume of distribution  
VZV  varicella zoster virus  
WBC  white blood cell  
WHO  World Health Organization  
WOCBP  women of childbearing potential  
 
ADC Therapeutics  Camidanlumab tesirine (ADCT -301) 
Final ADCT -301-201 Clinical Protocol  Protocol Amendment 5 
Date of Protocol  Amendment 5: 16 February 2022  Page 12 of 87 Summary of Changes 
The primary reason for Protocol Amendment 5 is to extend the contraception period after last 
dose of camidanlumab tesirine, following an urgent safety measure. The contraception period 
is determined based on the compound properties and half -life, and has been updated due to a 
recently revised half -life value of camidanlumab tesirine.  
• In Section  5.1, Inclusion criterion 10: For women of childbearing potential, the period 
of contraception after last dose of camidanlumab tesirine has been extended to at least 
9.5 months. For men with female  partners of childbearing potential the period of 
abstinence or use of condom has been extended to at least 6.5 months after last dose of 
camidanlumab tesirine. Section  7.4.6 Pregnancy Test, Section  8.6 Pregnancy 
Reporting, and Schedule of Assessments ( Table  1) have been revised accordingly. 
In addition, revisions to the protocol text have also been applied to the synopsis section. 
ADC Therapeutics  Camidanlumab tesirine (ADCT -301) 
Final ADCT -301-201 Clinical Protocol  Protocol Amendment 5 
Date of Protocol  Amendment 5: 16 February 2022  Page 13 of 87 List of Prior Protocol Versions 
Document  Version  Date Rationale for Changes  
Amendment 4  06 Nov 2020  The primary reasons for this global Protocol Amendment 4 
were to implement the recommendations from the independent Data and Safety Monitoring Board (iDSMB), including the addition of varicella zoster virus p rophylaxis, an update of the 
management guidance in respect to specific autoimmune 
toxicities, and to address the requests from the French and Belgian regulatory authorities.  
Amendment 3  01 Jul 2020  The primary reason for this global Protocol Amendment 3 was to update the stopping rule and to exclude patients that are 
tested positive for influenza and respiratory syndrome 
coronavirus 2 (SARS -CoV- 2) before initiating study 
treatment, based on the recommendations by the Food and Drug Administration (FDA).  
Amendment 2 24 Apr 2020  The primary reason for this global Protocol Amendment 2 was to combine the updates required by the Regulatory Authorities 
and Institutional Review Boards (IRB)/Independent Ethics 
Committees (IEC) received to date in one global protoc ol 
version. In addition, updates in line with study needs had  been 
introduced, such as the inclusion of severe acute respiratory syndrome coronavirus 2 (SARS -CoV-2) added to the list of 
pathogens associated to Guillain -Barré syndrome (GBS ), 
additional 
recommendation to capture early signs of 
polyradiculopathy/GBS, and the update of the study stopping rule. 
Amendment 1  24 Jun 2019  The primary reason for Protocol Amendment 1 was to include changes based on recommendations by the  US Food and Drug 
Administration. In addition, substantial updates in line with study needs had been introduced, e.g., revision of study drug 
instructions or clarifications of male participant contraception methods.
 
Version 2  15 Mar 2019  The primary reasons for Protocol Version 2 (15 March 2019) 
were to include changes based on internal discussion and 
emerging data.  
This version is the first version that was used for submission purposes, thus to be considered as the actual Original Protocol . 
Original Protocol  12 Jul 2018  This version has been distributed to sites but not for 
submission purposes.  
 
ADC Therapeutics  Camidanlumab tesirine (ADCT -301) 
Final ADCT -301-201 Clinical Protocol  Protocol Amendment 5 
Date of Protocol  Amendment 5: 16 February 2022  Page 14 of 87 Protocol Synopsis  
Protocol Number:  ADCT -301-201  
Title: A Phase 2, Open-label, Single -Arm Study to E valuate the Efficacy and 
Safety of Camidanlumab Tesirine (ADCT -301) in Patients with Relapsed 
or Refractory Hodgkin L ymphoma 
Sponsor:  ADC Therapeutics SA  
Study Phase:  Phase 2 
Indication:  Classical Hodgkin Lymphoma ( cHL, also known as classical 
Hodgkin  Disease)  
Rationale:  Camidanlumab tesirine is an antibody -drug conjugate (ADC) that has been 
designed to target and kill CD25-expressing cells. Given the encouraging 
overall response rate ( ORR ) and complete response (CR) rate reported with 
camidanlumab tesirine in the Phase 1 study in relapsed and refractory 
Hodgkin lymphoma (HL) patients at dose levels below the maximum 
tolerated dose (MTD ) and the acceptable safety profile, camidanlumab 
tesirine presents a positive risk -benefit for further evaluation in this 
population. 
Objectives:  Primary Objective  
• Evaluate th e efficacy of single agent camidanlumab tesirine in 
patients with relapsed or refractory HL  
Secondary Objectives  
• Characterize additional efficacy endpoints of camidanlumab tesirine 
• Characterize the safety profile of camidanlumab tesirine 
• Characterize the pharmacokinetic (PK) profile of camidanlumab 
tesirine  
• Evaluate the immunogenicity of camidanlumab tesirine  
• Evaluate the impact of camidanlumab tesirine treatment on health -
related quality of life (HRQoL)  
Exploratory Objectives 
• Assess the p harmacodynamic  effects of camidanlumab tesirine 
• Characterize tumor and t umor -associated non -tumor cells (TANT), as 
well as immunological relevant parameters, in baseline tumor tissue  
• Evaluate genetic alterations characterizing HL and their evolution 
upon camidanlumab tesir ine treatment  
• Explore exposure -response relationships affecting safety and efficacy 
of camidanlumab tesirine 
• Explore correlations between clinical activity or safety of 
camidanlumab tesirine and tumor and/or blood biomarkers  
ADC Therapeutics  Camidanlumab tesirine (ADCT -301) 
Final ADCT -301-201 Clinical Protocol  Protocol Amendment 5 
Date of Protocol  Amendment 5: 16 February 2022  Page 15 of 87 Endpoints: Primary Endpoints 
• ORR according to the 2014 Lugano classification as determined by 
central review 
Secondary Endpoints 
• Duration of response (DOR)  
• CR rate  
• Relapse-free survival (RFS)  
• Progression -free survival (PFS)  
• Overall survival (OS)  
• Fraction of patients receiving hematopoietic stem cell transplant  
(HSCT)  
• Frequency and severity of adverse events (AE s) and serious adverse 
events (SAEs)  
• Changes from Baseline of safety laboratory values, vital signs, 
Eastern  Cooperative Oncology Group (ECOG) performance status, 
and 12-lead electrocardiograms (ECGs)  
• Concentrations and PK parameters of camidanlumab tesirine total 
antibody, pyrrolobenzodiazepine (PBD)- conjugated antibody, and 
unconjugated warhead SG3199  
• Frequency of confirmed positive anti -drug antibody (ADA) 
responses, their associated (ADA) titers and, if applicable, 
neutralizing activity to camidanlumab tesirine after treatment with 
camidanlumab tesirine  
• Change from Baseline in HRQoL as measured by EuroQo L–5 
Dimensions–5 Levels (EQ-5D -5L) and Functional Assessment of 
Cancer Therapy – Lymphoma (FACT -Lym)  
Exploratory Endpoints  
• Changes in levels of immunologically relevant biomarkers in blood such as, but not limited to , interleukin -2 (IL -2), IL -10, and soluble 
CD25 (sCD25)  
• Measurement of CD25(+) tumor cells and TANT in baseline tumor 
tissue  
• Measurement of tumor infiltrating lymphocytes (TILs) and other 
immunologically relevant parameters in baseline tumor tissue 
• Detect HL alterations in plasma circulating free DNA ( cfDNA) prior, 
during, and after camidanlumab tesirine tr eatment, including at 
disease progression  
• Monitor residual disease prior to camidanlumab treatment and upon disease progression  
• Relation between exposure (camidanlumab tesirine dose, PK metrics) and selected efficacy and safety endpoints 
• Relation between tumor and/or blood biomarkers and selected 
efficacy and safety endpoints 
ADC Therapeutics  Camidanlumab tesirine (ADCT -301) 
Final ADCT -301-201 Clinical Protocol  Protocol Amendment 5 
Date of Protocol  Amendment 5: 16 February 2022  Page 16 of 87 Study Design:  This is a Phase 2, multi-center, open -label, single -arm study.  
Patient Selection:  Inclusion Criteria:  
1. Written informed consent must be obtained prior to any procedures . 
2. Male or female patient s aged 18 years or older.  
For US  sites only: Male or female patient s aged 16 years or older.  
3. Pathologic diagnosis of cHL. 
4. Patients with relapsed or refractory cHL , who have received at least 
3 prior lines of systemic therapy (or at least 2 prior lines in 
HSCT  ineligible patients) including  brentuximab vedotin and a 
checkpoint inhibitor approved for cHL (e. g., nivolumab or 
pembrolizumab) . 
Note 1: Receipt of HSCT to  be included in the number of prior therapies 
needed to meet eligibility.  
Note 2: The reason(s) for HSCT ineligibility must be documented  in 
patient medical records/source documents and eCRF . 
5. Measurable disease as defined by the 2014 Lugano Classification . 
6. Availability of formalin -fixed paraffin -embedded (FFPE) tumor tissue 
block (or minimum 10 freshly cut unstained slides if block is not 
available) . 
Note 1 : Any biopsy since initial diagnosis is acceptable, but if several 
samples are available, the most recent sample is preferred . 
Note 2: If a sufficient amount of  tissue is not available, a fresh biopsy 
may be taken , provided the procedure is not deemed high-risk and is 
clinically feasible , and provided it  is approved locally.  
7. ECOG performance status 0 -2. 
8. Adequate organ function as defined by Screening laboratory values 
within the following parameters:  
a. Absol ute neutrophil count (ANC) ≥  1.0 × 103/µL (off growth factors 
at least 72 h).  
b. Platelet count ≥  75 × 103/µL without transfusion in the past 2 weeks. 
c. Alan ine aminotransferase (ALT), aspartate aminotransferase 
(AST), or gamma glutamyl transferase (GGT) ≤ 2.5 × the upper 
limit of normal (ULN)  if there is no liver involvement ; ALT or 
AST  ≤ 5 × ULN if there is liver involvement. 
d. Total bilirubin ≤  1.5 × ULN (patients with known Gilbert’s 
syndrome may have a total bilirubin up to ≤  3 × ULN with direct 
bilirubin  ≤ 1.5 × ULN).  
e. Blood creatinine ≤ 3.0 × ULN or calculated creatinine 
clearance ≥ 30 mL/min by the Cockcroft -Gault equation.  
ADC Therapeutics  Camidanlumab tesirine (ADCT -301) 
Final ADCT -301-201 Clinical Protocol  Protocol Amendment 5 
Date of Protocol  Amendment 5: 16 February 2022  Page 17 of 87 Note: A laboratory assessment may be repeated a maximum of two 
times during the Screening P eriod to confirm eligibility.  
9. Negative beta-human chorionic gonadotropin (β -HCG) pregnancy test 
within 7 days prior to start of study drug for women of childbearing 
potential.  
10. Women of childbearing potential must agree to use a highly effective method of contraception from the time of giving informed consent until at least 9.5  months  after the last dose of camidanlumab tesirine. Men 
with female partners who are of chi ldbearing potential must agree to 
use condom when sexually active or practice total abstinence from the 
time of giving informed consent until at least 6.5 months  after the 
patient receives his last dose of camidanlumab tesirine. 
Exclusion Criteria:  
1. Previous treatment with camidanlumab tesirine.  
2. Participation in another investigational interventional study.  
Being in follow -up of another investigational study is allowed.  
3. Known history of hypersensitivity to or positive serum human ADA to a CD25 antibod y. 
4. Allogenic or autologous HSCT within 60 days prior to start of study 
drug.  
5. Active graft-versus-host disease (GVHD), except for non -neurologic 
symptoms as a manifestation of mild ( ≤ Grade 1) chronic GVHD.  
6. Post-HSCT  lymphoproliferative disorders . 
7. Active second primary malignancy other than non- melanoma skin 
cancers, non -metastatic prostate cancer, in situ cervical cancer, ductal 
or lobular carcinoma in situ of the breast, or other malignancy that the Sponsor’s medical monitor and Investigator agree and document should not be exclusionary. 
8. History of symptomatic autoimmune disease (e.g., rheumatoid 
arthritis, systemic progressive sclerosis [scleroderma], systemic 
lupus erythematosus, Sjögren’ s syndrome, autoimmune vasculitis  
[e.g., Wegener ’s granulomatosis ]) (subjects with vitiligo, type 1 
diabetes mellitus, residual hypothyroidism, hypophysitis due to 
autoimmune condition only requiring hormone replacement may be enrolled) . 
9. History of neuropathy considered of autoimmune origin  
(e.g., polyradiculopathy including Guillain -Barré syndrome and 
myasthenia gravis) or other central nervous system autoimmune 
disease (e.g., poliomyelitis, multiple sclerosis). 
10. History of recent infection (within 4 weeks of Cycle 1, Day  1 
[C1D1]) considered to be caused by one of t he following pathogens: 
HSV1, HSV2, VZV, EBV, CMV, measles, Influenza A, Zika virus, Chikungunya virus, mycoplasma pneumonia, Campylobacter jejuni , 
enterovirus D68, or severe acute respiratory syndrome coronavirus  2 
(SARS -CoV- 2). 
ADC Therapeutics  Camidanlumab tesirine (ADCT -301) 
Final ADCT -301-201 Clinical Protocol  Protocol Amendment 5 
Date of Protocol  Amendment 5: 16 February 2022  Page 18 of 87 Note : An i nfluenza  test and a pathogen -directed  SARS -CoV -2 test  
(such as polymerase chain reaction)  are mandatory and must be 
negative before initiating study treatment (tests to be performed 
3 days or less prior to dosing on C1D1 ; an additional 2 days are 
allowed in the event of logistical issues for receiv ing the results on 
time). 
11. Patients known to be or having been infected with human 
immunodeficiency (HIV) virus, hepatitis B virus (HBV), or 
hepatitis  C virus (HCV), and require  anti-viral therapy  or 
prophylaxis . 
Note: Serology  testing is mandatory for patients with unknown 
status. 
12. History of Stevens-Johnson syndrome or toxic epidermal necrolysis . 
13. Failure to recover ≤  Grade 1 (Common Terminology Criteria for 
Adverse Events version 4.0 [CTCAE v4.0]) from acute 
non-hematologic toxicity (except ≤  Grade 2 neuropathy or alopecia), 
due to previous therapy, prior to screening. 
14. HL with central nervous system  involvement, including 
leptomeningeal disease. 
15. Clinically significant third space fluid accumulation (i.e., ascites 
requiring drainage or pleural effusion that is either requiring drainage 
or associated with shortness of breath) . 
16. Breastfeeding or pregnant . 
17. Significant medical comorbidities, including uncontrolled 
hypertension (blood pressure [BP] ≥ 160/100 mmHg repeatedly), 
unstable a ngina, congestive heart failure (greater than New York 
Heart Association class II), electrocardiographic evidence of acute 
ischemia, coronary angioplasty or myocardial infarction within 
3 months prior to screening, severe uncontrolled atrial or ventricular  
cardiac arrhythmia, poorly controlled diabetes, or severe chronic 
pulmonary disease . 
18. Major surgery, radiotherapy, chemotherapy , or other anti -neoplastic 
therapy, within 14 days prior to start of study drug, except shorter if approved by the Sponsor.  
19. Use of any other experimental medication within 30  days prior to 
start of study drug. 
20. Any live vaccine within 4 weeks prior to start of study drug and 
planned live vaccine administration after starting study drug . 
21. Congenital long QT syndrome, or a corrected QTc interval of 
≥ 480 ms, at screening (unless secondary to pacemaker or bundle 
branch block).  
22. Any other significant medical illness, abnormality, or condition that would, in the Investigator’s judgment, make the  patient inappropriate 
for study participation or put the patient at risk. 
ADC Therapeutics  Camidanlumab tesirine (ADCT -301) 
Final ADCT -301-201 Clinical Protocol  Protocol Amendment 5 
Date of Protocol  Amendment 5: 16 February 2022  Page 19 of 87 Estimated Duration 
of Patient 
Participation and 
Study Duration:  The duration of the study participation for each patient is defined as the time from the date of signed written info rmed consent to the completion of 
the follow -up period, withdrawal of consent, loss to follow -up, or death, 
whichever occurs first.  
The study will include a Screening Period (of up to 28 days), 
a Treatment  Period (cycles of 3  weeks), and a Follow -up Period  
(approximately every 12 -week visits) for up to 3 years from End of 
Treatment (EOT) . 
Patients may continue treatment until disease progression, unacceptable toxicity, or other discontinuation criteria , whichever occurs first . 
The overall end of study occurs at the last visit or last scheduled procedure for the last patient, unless the study is terminated earlier by Sponsor.  
Efficacy Assessments:  • Disease assessments: Positron emission tomography -computed 
tomography (PET -CT) 
Note: If disease is not PET -avid at baseline, CT or MRI may be used 
for follow-up disease assessments. The assessment method determined 
to identify sites of disease at Baseline should be used for all subsequent assessments.  
Safety Assessments:  • Physical examination , incl uding  neurological examination  
• ECOG performance status  
• Height and weight  
• Vital signs  
• Safety laboratories (hematology, chemistry, coagulation, urinalysis, and as applicable, viral detection and/or additional microbiological 
studies) 
• Pregnancy test, if applicable 
• 12 Lead -ECG (triplicate)  
• AEs/SAE s, graded according to CTCAE version 4.0.  
Other Assessments:  • Blood sampling for PK, ADA, and biomarkers  
• Tumor tissue for biomarkers  
• HRQoL: EQ -5D-5L and FACT -Lym 
Study Drug, Dosage, 
and Mode of Administration:
 Camidanlumab  tesirine will be administered in 3 -week cycles as an 
intravenous ( IV) infusion over 30 minutes on Day 1 of each cycle. 
Patients  will receive 45 µg/kg for 2 cycles, then  30 µg/kg for subsequent 
cycles.  
Sample Size:  The sample size of 100 patients will provide a robust population for safety evaluation and adequate precision for observed ORR in the expected range. For the test of efficacy, this study has >98% power to distinguish between an active therapy with a 55% true response rate from a therapy with a response rate of 35% or less with a 1 -sided alpha of 0.025.  
ADC Therapeutics  Camidanlumab tesirine (ADCT -301) 
Final ADCT -301-201 Clinical Protocol  Protocol Amendment 5 
Date of Protocol  Amendment 5: 16 February 2022  Page 20 of 87 Statistical 
Considerations:  Statistical Analysis:  
ORR, CR rate with 95% confidence interval ( CI) from all-treated patients 
will be presented.  
DOR, RFS, PFS, and OS will be analyzed in Kaplan -Meier approach.  
Safety analyses will be presented descriptively.  
 
ADC Therapeutics  Camidanlumab tesirine (ADCT -301) 
Final ADCT -301-201 Clinical Protocol  Protocol Amendment  5 
Date of Protocol  Amendment 5: 16 February 2022  Page 21 of 87 Schedule of Events 
Table  1 Schedule of Events  
 Protocol 
Section  Screening  Treatment Period  Follow -up Period  
(up to 3 year s from EOT)  
(1 Cycle = 21 days )   Cycle 1 and Cycle  2 (C1 and C2)  C3 and beyond  EOT  Every 12 weeks  (wks)  
Day (D)   -28 to –1 1 8 15 1   
Informed consent  7.1 X       
Eligibility criteria  5.1 
5.2 X       
Demography  7.2 X       
Medical/Cancer history  7.2 X       
Tumor tissue shipment  7.5.3.2  X upon 
confirmed 
eligibility        
Disease assessment  7.3 X1 6 weeks and 12 weeks after C1D1, then every 9 wks1 X1 Every 12 weeks until 1 year from 
EOT, then every 6 months until 
disease progression2 
Physical examination,  
incl. neurological examination  7.4.1  X X X X X X  
ECOG performance status  7.4.2  X X   X X  
Height  7.4.3  X       
Weight  7.4.3  X X X X X X  
Vital signs (BP, HR, RR, Temp)  7.4.4  X X3 X X X3 X  
Hematology and Chemistry  7.4.5  X X X X X X  
Coagulation and Urinalysis  7.4.5  X X    X  
Thyroid function  tests 7.4.5  X On C1D1 , thereafter on D1 of every other cycle  X  
Influenza and SARS -CoV -2 7.4.5  3 days4 or less prior to 
dosing on C1D1       
Viral detection , if applicable5 7.4.5 X On C1D1, thereafter on D1 of every other cycle  X  
Pregnancy test, if applicable  7.4.6  X On C1D1, thereafter on D1 of every other cycle  (max. 
6 wks apart ) X6  
ADC Therapeutics  Camidanlumab tesirine (ADCT -301) 
Final ADCT -301-201 Clinical Protocol  Protocol Amendment  5 
Date of Protocol  Amendment 5: 16 February 2022  Page 22 of 87  Protocol 
Section  Screening  Treatment Period  Follow -up Period  
(up to 3 year s from EOT)  
(1 Cycle = 21 days )   Cycle 1 and Cycle  2 (C1 and C2)  C3 and beyond  EOT  Every 12 weeks  (wks)  
Day (D)   -28 to –1 1 8 15 1   
12-lead ECG  7.4.7  
Table  3 X X 
(Pre, EOI, 
Post)  X X C3 and C4 (Pre, 
EOI), C5 then 
every other cycle 
(Pre)  X  
Premedication  6.7.1   D-1 to D2    D-1 to D2    
Camidanlumab tesirine  
administration  6.3  X   X   
PK sample  7.5.1  
Table  4  X 
(Pre, EOI, 
Post)  X X C3 through C6 
(Pre, EOI), then 
every cycle (Pre)  X  
ADA sample  7.5.2  
Table  4  X (Pre)   X 
C1 only  C3 (Pre), then 
every other cycle 
(Pre)  X7  
Soluble biomarkers  7.5.3.1  
Table  5  X 
(Pre, Post)  X X C3 (Pre, EOI), then 
every other cycle 
(Pre)  X  
cfDNA samples (gDNA only at 
C1D1 and EOT)  7.5.3.1   X (Pre)    6 and 12 weeks 
postdose  
(with disease 
assessment)  X X at disease progression  
HRQoL8 7.6  X   X X  
Concomitant medications9 6.8 From ICF signature date or D -14, whichever is earlier, until 30 days after last dose of study drug  
Adverse events  8 AE/SAEs from ICF signature date until 30 days after last dose of study drug; thereafter, related SAEs only  
1st New anticancer treatment  4.2.3       X X 
Survival  4.2.5       X X 
Abbreviations:  ADA, anti -drug antibody; AE,  adverse event; BP,  blood pressure ; cfDNA: circulating cell- free DNA; ECG, electrocardiogram; ECOG,  Eastern 
Cooperative Oncology Group; EOI, end of infusion; EOT, end of treatment; HR,  heart rate;  gDNA , genomic DNA; HRQoL , health -related quality of life; ICF, 
infor med consent form;  PK, pharmacokinetics; post, pos tdose; pre, predose; RR,  respiratory rate; SARS -CoV -2: respiratory syndrome coronavirus 2; SAE, serious 
adverse event ; Temp,  temperature ; VZV , varicella zoster virus . 
ADC Therapeutics  Camidanlumab tesirine (ADCT -301) 
Final ADCT -301-201 Clinical Protocol  Protocol Amendment  5 
Date of Protocol  Amendment 5: 16 February 2022  Page 23 of 87 1. Screening imaging must be performed within 4 weeks prior to C1D1 and the same assessment method should be used throughout the  study.  Week 6 imaging 
should be performed within 1 week prior to C3D1 and Week 12 imaging should be performed within 1 week prior to C5D1. All othe r imaging for disease 
assessment for patients on study drug should be performed within ±2 weeks of the scheduled ti mepoint. Disease assessments should be performed at the 
timepoints specified even if study drug dosing is delayed. If a scan has been performed within 6 weeks of EOT, it does not need to be repeated at EOT.  
2. Disease assessments to be performed in patients having discontinued study drug for reasons other than disease progression  or initiation of other anti -cancer 
therapy (except for hematopoietic  stem cell transplant  or CAR -T therapy ). 
3. Vital signs to be measured predose and at EOI.  
4. Additional 2 days are allo wed in the event of logistical issues for receiving  the results on time.  
5. Serology testing for human immunodeficiency virus, hepatitis B virus, or hepatitis C virus  is mandatory at screening for patients with unknown status. 
Seropositive patients for or wi th prior history of these infections  at screening  will be tested during the study  (not needed if seropositivity is only due to 
vaccination) .  
6. The EOT visit pregnancy test should be performed ≥ 9.5 months  after the last dose of study drug.   
7. Patients who test  positive for ADAs will be requested to supply additional ADA samples.  
8. FACT -Lym  not to be administered for patients  <18 years old.  
9. VZV prophylaxis is recommended for all enrolled patients  as indicated in Section  6.7.6 . 
 
Visit Scheduling Windows:  
• Treatment Period: visit day ± 2 days  (excluding C1D1 which is the reference day)  
• EOT: a s soon as possible after decision to discontinue the study drug , preferably within 30 days after last dose of study drug, and before initiation of any 
new anticancer treatmen t  
• Follow -up Period: visit day ± 14 days  
 
ADC Therapeutics  Camidanlumab tesirine (ADCT -301) 
Final ADCT -301-201 Clinical Protocol  Protocol Amendment 5 
Date of Protocol Amendment 5: 16 February 2022  Page 24 of 87 1 Introduction and Background 
1.1 Targeting CD25- positive T umor Cells in Hodgkin Lymphoma 
Hodgkin lymphoma (HL) is a lymphoid malignancy of B -cell origin, which is classified into 
either nodular lymphocyte predominant Hodgkin lymphoma or classical Hodgkin lymphoma 
(cHL). The latter accounts for 95% of all HLs  and is addressed by this protocol  (Fields , 2017) . 
Thus, for convenience, cHL/HL will be used interchangeably. 
The epidemiology of HL is characterized by bimodal incidence (15- 34 years and 55+ years). 
Therapeutic advances have resulted in durable remission rates of 60 -80%. However, there is 
an unmet medical need for patients’ refractory or relapsing from current treatments. Since 
many of these patients are of young age, the potential loss of life years is significant 
(Mehta -Shah, 2018;  Fields , 2017; Glimelius , 2017). 
Brentuximab vedotin as a single agent and checkpoint inhibitors have been approved for use in the relapsed setting, and thus patients coming onto this trial should have received both of these therapies. Howeve r, once these therapies fail or are not tolerated, treatment options are 
limited  (Mehta -Shah , 2018; Mottok, 2018; Fields , 2017; Glimelius , 201 7). It is in this setting 
where camidanlumab tesirine, an antibody -drug conjugate that is directed against human 
cluster of differentiation (CD25 ), will be clinically tested.  
The CD25 is the alpha -chain of the interleukin ( IL)-2 receptor and as such expressed on the 
cell surface of a number of normal cells of the immune system  as well as malignant cells 
(Flynn, 2017). 
The presence of CD25- positive cells in hematologic malignancies and the relationship between 
increased CD25 expression and poor prognosis raises the possibility of using an anti -CD25 
antibody to deliver a cytotoxin to these cells in patients. Hematologic malignancies expressing CD25 include adult T -cell leukemia ( Waldmann,  1995), hairy cell leukemia ( Shao , 2013), 
anaplastic large cell lymphoma ( Strauchen, 1987), cutaneous T -cell lymphoma ( Olsen , 2001; 
Prince , 2010 ), chronic lymphocytic leukemia ( Shvidel, 2012), HL (Schnell, 1998), follicular 
lymphoma ( Fujiwara , 2013a ), diffuse large B -cell lymphoma ( Fujiwara , 2013b), acute myeloid 
leukemia ( Cerny , 2013), acute lymphocytic leukemia (Geng , 2012), and systemic mastocytosis 
(Lim, 2009). Expression of CD25 is positive ( ≥ 20% tumor cells) in approximately 58% to 
78% of HL ( Strauchen , 1987; LeMaistre, 1998). 
1.2 Description of Investigational Study Drug 
Camidanlumab tesirine (ADCT -301) is an antibody- drug conjugate ( ADC ), composed of the 
human monoclonal antibody, HuMax®-TAC, which is directed against human CD25. 
The antibody is conjugated through a protease cleavable linker to SG3199, 
a pyrrolobenzodiazepine (PBD) dimer cytotoxin. 
The schematic representation of camidanlumab tesirine  is presented in  Figure  1. 
ADC Therapeutics  Camidanlumab tesirine (ADCT -301) 
Final ADCT -301-201 Clinical Protocol  Protocol Amendment 5 
Date of Protocol Amendment 5: 16 February 2022  Page 26 of 87 Treatment -emergent adver se events (TEAEs) were reported in 73 (97%) out of 77 c HL patients 
treated with camidanlumab tesirine. Overall, the most common TEAE s (observed in at least in 
15% of patients), regardless of causality , included: fatigue ( 42%); rash maculopapular (35%); 
pyrexia (29%); gamma  glutamyl transferase (GGT) increased (26%); nausea (25%);  
alanine aminotransferase (ALT)  increased  (24%);  aspartate aminotransferase (AST) increased  
and cough (21% each);  rash (20%); dyspnea (18%); blood alkaline phosphatase (ALP) 
increased  and anemia (1 7% each ); and abdominal pain and constipation (16% each ). 
The TEAEs  ≥ Grade 3  were reported in 51 (66%) cHL patients , with the most co mmon 
(observed in at least 5% of patients), regardless of causality , including: GGT  increased and 
rash maculopapular ( 17% each); ALT  increased ( 9%); anemia  (8%); AST  increased  and 
Guillain -Barré syndrome (GBS)/radiculopathy (7% each); and lipase increased ( 5%). 
The TEAEs in 20 (26 %) patients led to treatment discontinuation . At the dose level of 45 µg /kg, 
approximately 89% of HL patients tolerated at least 2 cycles of camidanlumab tesirine before 
an AE leading to dose delay/modification occurred. 
Treatment -emergent s erious adverse events ( SAEs ), irrespective of causality, were reported in  
36 (47%) out of 77 HL patients. Of these, 24 patients ( 31%) experienced a  treatment- emergent  
SAE(s) considered at least possibly related to study drug. The following drug -related 
treatment- emergent SAEs were observed in multiple patients: pyrexia (6), GBS/radicu lopathy 
(5), dyspnea (4), pleural effusion  (4), acute kidney injury  (2), blood creatine phosphokinase 
increased  (2), cough (2), febrile neutropenia  (2), nausea  (2), edema peripheral  (2), stomatitis  
(2), and vomiting  (2). 
Out of 37 evaluable patients with cHL at the dose of 45 µg/kg Q3W, 18 (49%) achieved 
complete response (CR) and 14 (38%) achieved partial response (PR), for an overall response rate (ORR) of 87%, as per Investigator evaluation. Albeit with lower observed response rates, 30 µg/kg Q3W is an active dose (ORR 50%, 9/18 patients), with both CR (28%) and PR (22%) 
observations. The lowest dose in which antitumor activity has been observed was 13 µg/kg 
Q3W.  
Taking into account all patients treated with camidanlumab tesirine  (as of the date of this 
protocol amendment) , GBS, dyspnea, pleural effusion, rash, and maculopapular rash have been 
classified as expected serious adverse drug reactions. All events of GBS, even though expected, 
will continue to be subject to expedited reporting. 
As of the date o f this protocol amendment, a total of 8 patients with treatment-emergent 
GBS/polyradiculopathy events were reported across the entire camidanlumab tesirine 
development program  including 4 studies, 2 of which reported such cases : 5 cHL patients in 
the Phase 1 study (described above) and 3 cHL patients in  this ongoing Phase 2 study.  
Neurologic and immune -related adverse events (A Es) including polyradiculopathy and GBS 
have been classified as important identified risks. Increased liver enzymes, skin toxicity 
(epidermal degeneration), and nephropathy have been classified as important potential risks.  
Additional details may be found in the current  camidanlumab tesirine ( ADCT -301) 
Investigator’s Brochure (IB).  
ADC Therapeutics  Camidanlumab tesirine (ADCT -301) 
Final ADCT -301-201 Clinical Protocol  Protocol Amendment 5 
Date of Protocol Amendment 5: 16 February 2022  Page 27 of 87 2 Study Rationale  
Camidanlumab tesirine is an ADC that has been designed to target and kill CD25 -expressing 
cells. Given the encouraging ORR and complete response (CR) rate reported with 
camidanlumab tesirine in the Phase 1 study in relapse d and refractory HL at dose levels below 
the MTD and the acceptable safety profile ( Section  1.3), camidanlumab tesirine presents a 
positive risk -benefit for further ev aluation in this population. 
2.1 Rationale for Study Design 
This is a Phase 2, open-label, single- arm study and will enroll approximately 100 patients.  
A single -arm design is commonly used to evaluate efficacy as a primary objective and the 
benefit- risk ratio of an oncology product with considerable anti -tumor activity within a 
well-defined patient population with high unmet medical need. O verall response rate  is 
considered an appropriate endpoint in this setting.  
Additionally, because of the considerable ORR observed in the ADCT -301- 001 Phase  1 trial 
in HL patients and the anticipated recruitment projections, an interim analysis for futility is not 
warranted.  
2.2 Rationale for Dose Selection 
Doses ranging from 3 µg/kg Q3W up to 300 µg/kg Q3W were  planned to be investigated in 
the FIH camidanlumab tesirine clinical stud y ADCT -301-001, which target CD25-positive 
tumors ( Section  1.3); the highest dose level tested as of  14 April 2019 was 150 µg/kg Q3W 
and the MTD had not been reached. The recommended dose for Phase  2 for HL has been 
determined as 45  µg/kg Q3W dosed for 2 cycles, followed by 30 µg/kg Q3W. 
The decision for initial dosing at the 45 µg/kg Q3W dose level is based on a number of considerations including: 
1) the favorable ORR ( 87%) and CR rate (49%)  together with an acceptable safety profile  
2) the high fraction of  patients with cHL who could tolerate at least 2 cycles of 
camidanlumab tesirine before an AE leading to a dose delay/modification occurred  
3) the ability to manage some of the severe TEAEs at this  dose level  
Given that the attribution of toxicity to disease itself can be variable, it is recognized that a relatively high incidence of severe TEAEs in the relapsed/refractory lymphoma population is not uncommon. 
Dose reduction from 45 to 30 µg/kg following 2 cycles of camidanlumab tesirine Q3W 
treatment would provide lower dose intensity , while still being an active dose (ORR 56%) , 
which can mitigate the frequency and severity of A Es foreseen in patients treated with 45  µg/kg 
beyond 2 cycles.  
ADC Therapeutics  Camidanlumab tesirine (ADCT -301) 
Final ADCT -301-201 Clinical Protocol  Protocol Amendment 5 
Date of Protocol Amendment 5: 16 February 2022  Page 28 of 87 Continued dosing at a reduced dose of 30 µg/kg with demonstrated ant itumor activity is 
expected to decrease the necessity for dose delay/modification due to toxicity and thus increase 
the duration of response (DOR) . 
Therefore, the safety profile of camidanlumab tesirine administered as 45  µg/kg Q3W for 
2 cycles,  then 30 µg /kg Q3W thereafter is considered a reasonable regimen to investigate in 
patients with cHL , which can optimize potential response to treatment while maintaining an 
acceptable degree of manageable toxicity.  
 
ADC Therapeutics  Camidanlumab tesirine (ADCT -301) 
Final ADCT -301-201 Clinical Protocol  Protocol Amendment 5 
Date of Protocol Amendment 5: 16 February 2022  Page 29 of 87 3 Study Objectives  and Endpoints  
Study objectives and associated endpoints are presented below in Table  2. 
Table  2 Study Objectives and Endpoints   
Objectives  Endpoints  
Primary  
Evaluate the efficacy of single agent camidanlumab tesirine 
in patients with relapsed or refractory HL • ORR according to the 2014 Lugano classification as determined by central 
review in all -treated patients  
Secondary 
Characterize additional efficacy endp oints of camidanlumab 
tesirine  • DOR defined as the time from the first documentation of tumor response to 
disease progression or death  
• CR rate defined as the percentage of treated patients with a best overall 
response (BOR) of CR 
• Relapse-free survival (RFS) defined as the time from the documentation of 
CR to  disease progression or death  
• Progression -free survival ( PFS) defined as the time from first dose of study 
drug until the first date of either disease progression or death due t o any cause  
• Overall survival ( OS) defined as the time from first dose of study drug until  
death due to any cause 
• Fraction of patients receiving hematopoietic stem cell transplant  (HSCT ). 
Characterize the safety profile of camidanlumab tesirine  • Frequency and severity of A Es and SAEs  
• Changes from Baseline of safety laboratory values, vital signs, 
Eastern  Cooperative Oncology Group (ECOG) performance status, and 12-
lead electrocardiograms (ECGs)  
Characterize  the PK profile of camidanlumab tesirine  • Concentra tions and PK parameters of camidanlumab tesirine  total antibody, 
PBD -conjugated antibody, and unconjugated warhead SG3199   
Evaluate the immunogenic ity of camidanlumab tesirine  • Frequency of confirmed positive a nti-drug antibody (ADA)  responses, their 
associated ADA titers and, if applicable, neutralizing activity to 
camidanlumab tesirine  after treatment with camidanlumab tesirine  
ADC Therapeutics  Camidanlumab tesirine (ADCT -301) 
Final ADCT -301-201 Clinical Protocol  Protocol Amendment 5 
Date of Protocol Amendment 5: 16 February 2022  Page 30 of 87 Objectives  Endpoints  
Evaluate the impact of camidanlumab tesirine treatment on 
health -related quality of life (HRQoL)  • Change from Baseline in HRQoL as measured by EuroQoL –5 
Dimensions – 5 Levels (EQ-5D -5L) and Functional Assessment of Cancer 
Therapy – Lymphoma (FACT -Lym)  
Exploratory  
Assess the pharmacodynamic  effect s of camidanlumab 
tesirine  • Changes in levels  of immunologically relevant biomarkers  in blood  such as 
but not limited to  IL-2, IL -10, and soluble CD25 ( sCD25 )  
Characterize tumor and tumor -associated non -tumor cells 
(TANT), as well as immunological relevant parameters in 
tumor tissue  • Measurement of  CD25(+)  tumor cells and TANT in baseline tumor tissue  
• Measurement of tumor i nfiltrating lymphocytes (TILs) and other 
immunologically relevant parameters  in baseline tumor tissue  
Evaluate genetic alterations characterizing HL and their 
evolution upon camidanlumab tesirine treatment  • Detect HL alterations in plasma circulating free DNA (cfDNA) prior, during, 
and after camidanlumab tesirine treatment, including at disease progression  
• Monitor residual disease prior to camidanlumab  tesirine treatment and upon 
disease progression  
Explore exposure -response relationships affecting safety and 
efficacy of camidanlumab tesirine  • Relation between exposure (camidanlumab tesirine dose, PK metrics) and 
selected efficacy and safety endpoints  
Explore correlations between clinical activity or safety of 
camidanlumab tesirine and tumor and/or blood biomarkers  • Relation between tumor and/or blood biomarkers and selected efficacy and 
safety endpoints  
 
 
ADC Therapeutics  Camidanlumab tesirine (ADCT -301) 
Final ADCT -301-201 Clinical Protocol  Protocol Amendment 5 
Date of Protocol Amendment 5: 16 February 2022  Page 31 of 87 4 Study Design  
4.1 Overview  
This is a Phase 2, multi-center, open- label , single- arm study.  
The duration of the study participation for each patient is defined as the time from the date of 
signed written informed consent to the completion of the follow -up period, withdrawal of 
consent, loss to follow-up, or death, whichever occurs first. 
The study will include a Screening Period (of up to 28 days), a Treatment Period (cycles of 
3 weeks), and a Follow -up Period (approximately every 12 -week visits ) for up to 3 year s from 
End of Treatment (EOT)  (Section  4.2). 
An independent Data and Safety Monitoring Board (iDSMB) will be established to ensure the safety of patients enrolled in this study ( Section  8.7). 
4.2 Study Periods  
4.2.1 Screening Period 
Informed consent must be obtained for each patient and documented with a signed informed consent form (ICF) prior to any study procedures. Procedures  that are performed  as part of 
standard of care may be used to satisfy screening requirements if they are performed in the 
appropriate window . 
The Screening Period is from 28 days to 1 day prior  to the start of the study drug. The screening 
assessments should be performed within this period in order to assess the eligibility of the 
patient against the inclusion and exclusion criteria ( Section s 5.1 and 5.2, respectively).  
See Section  5.3 for the information to be collected on screening failures. 
4.2.2 Treatment Period 
The treatment period starts on the date when a patient receives the first dose of study drug and 
continues until the EOT  visit. 
A treatment cycle is defined as 3  weeks (i.e., 21 days). 
Patients may continue treatment for up to 1 year or until disease progression , unacceptable 
toxicity , or other discontinuation criteria  (Section  5.4), whichever  occurs first. 
Additionally,  patients benefiting clinically at 1 year may continue treatment after a case by 
case review with the Sponsor. 
4.2.3 End of Treatment 
An EOT  visit should be performed as soon as possible after the decision to discontinue the 
study drug, preferably within  30 days after last dose of study drug , and before initiation of any 
new anticancer treatment.  
ADC Therapeutics  Camidanlumab tesirine (ADCT -301) 
Final ADCT -301-201 Clinical Protocol  Protocol Amendment 5 
Date of Protocol Amendment 5: 16 February 2022  Page 32 of 87 When EOT coincides with a scheduled visit, the scheduled visit will become EOT.  
4.2.4 Follow -up Period 
All patients, regardless of disease status, will be followed every 12 weeks for up to 3 years 
from EOT , or until withdrawal of consent, loss to follow-up, or death, whichever occurs first. 
When disease assessment s are not planned for a follow -up visit, the visit can be done by phone.  
4.2.5 End of Study  
The end of study occurs at the last scheduled visit/ procedure for the last patient, unless the 
study is terminated earlier by Sponsor. The death date should be considered as the end of study 
(EOS) date for an individual patient whose survival status was informed at any later contact date.  
4.3 Study S topping Rules  
This study has no formal  study stopping rule. 
However, upon a confirmed case of GBS /polyradiculopathy of any grade , other ≥Grade  3 
relevant severe neurologic toxicity , or other ≥Grade  3 potentially immune -mediated toxicity , 
the sponsor will calculate the overall incidence rate of such events in the study. T he 
denominator used to calc ulate this rate will be the number of patients who have received at 
least 2  doses of study drug for GBS /polyradiculopathy  of any grade  and at least 1 dose of study 
drug for other ≥Grade 3 relevant severe neurologic and potentially immune -mediated toxicit ies.  
• Should the incidence of GBS /polyradiculopathy of any grade  reach a n incidence 
threshold  of >8.1% (8.1% being the incidence of GBS/polyradiculopathy cases  of any 
grade observed in the HL population of the ADCT -301- 001 Phase  1 study at 45 µg/kg), 
enrollment will be paused while a comprehensive safety review is completed and the 
iDSMB convenes to advise on study continuation based on their assessment of benefit- risk. 
• Should the incidence of other ≥Grade  3 relevant severe neurologic toxicity and 
potentially immune -mediated toxicity reach an incidence threshold of  >10.0% (10.0 % 
being consistent with observations made for checkpoint inhibitors ; Brahmer, 2018 and 
Davies, 2017),  enrollment will be paused while a comprehensive safety review is 
completed and the iDSMB convenes to advise on study continuation based on their assessment of benefit -risk. 
All ongoing patients who could receive clinical benefit will be allowed to continu e on the study 
after being informed of the new safety information and consenting to continuation. 
The Sponsor will notify Regulatory Agencies if the threshold has been exceeded and 
enrollment has been paused. 
ADC Therapeutics  Camidanlumab tesirine (ADCT -301) 
Final ADCT -301-201 Clinical Protocol  Protocol Amendment 5 
Date of Protocol Amendment 5: 16 February 2022  Page 33 of 87 5 Patient Population  
Patients must meet all inclu sion criteria and none of the ex clusion criteria to be eligible for the 
study. A ll criteria have to be assessed  at Screening , unless  otherwise specified  (e.g., criterion 
to be confirmed within 28 days to 1  day prior to the start of study drug  on Cycle  1, Day 1 
[C1D1 ]). 
5.1 Inclusion Criteria  
1. Written informed consent must be obtained prior to any procedures. 
2. Male or female patient s aged 18 years or older. 
For US sites only : Male or female patients aged 16 years or older.  
3. Pathologic diagnosis of c HL. 
4. Patients with relapsed or refractory cHL, who have received at least 3 prior lines of 
systemic therapy (or at least 2 prior lines in HSCT ineligible patients) including  
brentuximab vedotin and  a checkpoint inhibitor approved for cHL (e.g., nivolumab or 
pembrolizumab). 
Note 1: Receipt of HSCT to  be included in the number of prior therapies needed to 
meet eligibility.  
Note 2: The reason(s) for HSCT ineligibility must be documented  in patient medical 
records/source documents and eCRF. 
5. Measurable disease as defined by the 2014 Lugano Classification. 
6. Availability of formalin -fixed paraffin -embedded (FFPE) tumor tissue block 
(or minimum 10 freshly cut unstained slides if block is not available). Note  1: Any biopsy since initial diagnosis is acceptable, but if several samples are 
available, the most recent sample is preferred . 
Note 2: If a sufficient amount of  tissue is not available, a fresh biopsy may be taken, 
provided the procedure is not deemed high- risk and is clinically feasible, and provided 
it is approv ed locally. 
7. Eastern Cooperative Oncology Group ( ECOG) performance status 0 -2. 
8. Adequate organ function as defined by S creening laboratory values within the 
following parameters:  
a. Absolute neutrophil count (ANC) ≥  1.0 × 10
3/µL (off growth factors at least 72 h). 
b. Platelet count ≥  75 × 103/µL without transfusion in the past  2 weeks . 
c. ALT, AST, or GGT  ≤ 2.5 × the upper limit of normal (ULN) if there is no  liver 
involvement ; ALT or AST ≤  5 × ULN if there is liver involvement. 
d. Total bilirubin ≤  1.5 × ULN (patients with known Gilbert’s syndrome may have a 
total bilirubin up to ≤  3 × ULN with direct bilirubin ≤  1.5 × ULN). 
e. Blood creatinine ≤  3.0 × ULN  or c alculated creatinine clearance ≥  30 mL/min by 
the Cockcroft- Gault equation . 
ADC Therapeutics  Camidanlumab tesirine (ADCT -301) 
Final ADCT -301-201 Clinical Protocol  Protocol Amendment 5 
Date of Protocol Amendment 5: 16 February 2022  Page 34 of 87 Note: A laboratory assessment may be repeated a maximum of two times during the 
Screening P eriod to confirm eligibility.  
9. Negative beta- human chorionic gonadotropin (β -HCG) pregnancy test within 7 days 
prior to start of study drug for women of childbearing potential . 
10. Women of childbearing potential  (WOCBP) * must agree to use a highly effective** 
method of contraception from the time of giving informed consent until at least 
9.5 months after the last dose of camidanlumab tesirine . Men with female partners who  
are of childbearing potential must agree to  use a condom when sexually active or 
practice total abstinence  from the time of giving informed consent until at least 6.5  
months after the patient receives his last dose of camidanlumab tesirine . 
* Women of childbearing potential are defined as sexually mature women who have 
not undergone bilateral tubal ligation, bilateral oophorectomy, or hysterectomy; or who have not been postmenopausal. A postmenopausal state is defined as no 
menses for 12 months without an alternative medical cause. A high follicle stimulating hormone (FSH) level in the postmenopausal range may be used to 
confirm a postmenopausal state in women not using hormonal contraception or hormonal replacement therapy. However, in the absence of 12 months of amenorrhea, 
a single FSH measurement is insufficient.  
** Highly effective forms of birth control are methods that achieve a failure rate of less 
than 1% per year when used consistently and correctly. Highly effective forms of 
birth control inclu de: hormonal contraceptives associated with inhibition of 
ovulation (oral, injectable, patch, and intrauterine  devices), male partner sterilization, 
or total abstinence from heterosexual intercourse, when this is the preferred and usual lifestyle of the patient.  
Note: The double -barrier method (e.g., synthetic condoms, diaphragm, or cervical cap 
with spermicidal foam, cream, or gel), periodic abstinence (such as calendar, symptothermal, postovulation), withdrawal (coitus interruptus), lactational amenorrhea method, and spermicide -only are not acceptable as highly effective methods of 
contraception. 
 
5.2 Exclusion Crit eria 
1. Previous treatment with camidanlumab tesirine.  
2. Participation in another investigational interventional study . Being in follow -up of 
another investigational study is allowed . 
3. Known history of hypersensitivity to or positive serum human anti- drug antibody  
(ADA) to a CD25 antibody. 
4. Allogenic or autologous HSCT within 60 days prior to start of study drug. 
5. Active graft -versus- host disease (GVHD), except for non- neurologic symptoms as a 
manifestation of mild (≤  Grade 1) chronic GVHD.  
6. Post-HSCT lymphoproliferative disorders . 
ADC Therapeutics  Camidanlumab tesirine (ADCT -301) 
Final ADCT -301-201 Clinical Protocol  Protocol Amendment 5 
Date of Protocol Amendment 5: 16 February 2022  Page 35 of 87 7. Active second primary malignancy other than non- melanoma skin cancers, 
non-metastatic prostate cancer, in situ cervical cancer, ductal or lobular carcinoma in 
situ of the breast, or other malignancy that the Sponsor’s medical  monitor and 
Investigator agree and document should not be exclusionary. 
8. History of symptomatic autoimmune disease (e.g., rheumatoid arthritis, systemic 
progressive sclerosis [scleroderma], systemic lupus erythematosus, Sjögren’s syndrome, autoimmune vasculitis [e.g., Wegener ’s granulomatosis]) 
(subjects with vitiligo, type 1 diabetes mellitus, residual hypothyroidism, hypophysitis 
due to autoimmune condition only requiring hormone replacement may be enrolled). 
9. History of neuropathy considered of autoimmune  origin (e.g., polyradiculopathy 
including Guillain -Barré syndrome and myasthenia gravis) or other central nervous 
system autoimmune disease (e.g., poliomyelitis, multiple sclerosis).  
10. History of recent infection (within 4 weeks of C1D1) considered to be caused by one of the following pathogens: HSV1, HSV2, VZV, EBV, CMV, measles, Influenza  A, 
Zika virus, Chikungunya virus, mycoplasma pneumonia, Campylobacter jejuni , 
enterovirus D68, or severe acute respiratory syndrome coronavirus 2 ( SARS -CoV-2) . 
Note: An i nfluenza test and a pathogen- directed SARS -CoV- 2 test (such as polymerase 
chain reaction  [PCR]) are mandatory and must be negative before initiating study 
treatment (tests to be performed 3 days or less prior to dosing on C1D1 ; an additional 
2 days are allowed in the event of logistical issues for receiv ing the results on time ). 
11. Patients who are carriers of human immunodeficiency (HIV) virus, hepatitis B virus (HBV), or hepatitis C virus (HCV), and require anti -viral therapy  or prophylaxis. 
Note: Serology t esting is mandatory for patients with unknown status. 
12. History of Stevens-Johnson syndrome or toxic epidermal necrolysis. 
13. Failure to recover ≤  Grade 1 (Common Terminology Criteria for Adverse Events 
version 4.0 [CTCAE v4.0]) from acute non- hematologic toxicity (except ≤  Grade  2 
neuropathy or alopecia), due to previous therapy, prior to screening. 
14. HL with central nervous system  involvement, including leptomeningeal disease. 
15. Clinically significant third space fluid accumulation (i.e., ascites  requiring drainage or 
pleural effusion that is either requiring drainage or associated with shortness of breath) . 
16. Breastfeeding or pregnant . 
17. Significant medical comorbidities, including uncontrolled hypertension (blood pressure [BP] ≥  160/100 mmHg repeatedly), unstable angina, congestive heart 
failure (greater than New York Heart Association class II), electrocardiographic evidence of acute ischemia, coronary angioplasty or myocardial infarction within 3 months prior to screening, severe uncontrolled atria l or ventricular cardiac 
arrhythmia, poorly controlled diabetes, or severe chronic pulmonary disease. 
18. Major surgery, radiotherapy, chemotherapy, or other anti -neoplastic therapy, 
within  14 days prior to start of study drug, except shorter if approved by the Sponsor. 
19. Use of any other experimental medication within 30  days prior to start of study drug. 
ADC Therapeutics  Camidanlumab tesirine (ADCT -301) 
Final ADCT -301-201 Clinical Protocol  Protocol Amendment 5 
Date of Protocol Amendment 5: 16 February 2022  Page 36 of 87 20. Any live vaccine within 4 weeks prior to start of study drug and planned live vaccine 
administration after starting study drug. 
21. Congenital long QT syndrome, or a corrected QTc interval of ≥  480 ms, at screening 
(unless secondary to pacemaker or bundle branch block). 
22. Any other significant medical illness, abnormality, or condition that would, in the Investigator’s judgment, make the patient inappropriate for study participation or put the patient at risk.  
 
5.3 Screening Failures  
Patients who signed the ICF but were found not eligible for the study prior to  receiving study 
drug are defined as screening failures.  
For these patients, only limited information will be col lected in the electronic case report form 
(eCRF ): 
- Informed consent  
- Demographics  
- Inclusion/exclusion criteria  
- SAE and/or death occurring during the Screening P eriod  
- Screening failure details  
 
5.4 Re-screening Procedures 
A patient who did not meet the eligibility criteria (screening failure) may be considered for re-screen ing. Decision for re -screening must be confirmed by the Sponsor /Medical monitor. 
A re-screened patient should be assigned  a new  patient number.  
5.5 Discontinuation  
The reason for discontinuation and the date of discontinuation will be collected for all patients. 
Note:  Once discontinued from the study for any reason, patients are not permitted to be 
re-enrolled. 
5.5.1 Discontinuation from Study Drug  
A patien t may be discontinued from the study drug  for any of the following reasons: 
• Planned for HSCT  
• Major protocol deviation  
• Discontinuation of the study by the Sponsor 
 
ADC Therapeutics  Camidanlumab tesirine (ADCT -301) 
Final ADCT -301-201 Clinical Protocol  Protocol Amendment 5 
Date of Protocol Amendment 5: 16 February 2022  Page 37 of 87 A patient must be discontinued from the study drug for any of the following reasons: 
• Investigator’ s decision  
• Patient decision  
• Disease progression (radiographic and/or clinical) based on Investigator ’s assessment   
• Unacceptable toxicity  
• Pregnancy 
• Death  
 
IMPORTANT:  Study drug discontinuation is not to be automatically considered as 
withdrawal from the study. Patients discontinuing the study drug will be asked to perform an 
EOT visit ( Section  4.2.3) and continue with the Follow -up period ( Section  4.2.4 ) as per 
protocol. 
The investigational site should make every effort to complete follow -up per protocol. 
If patients are unable to return to the site, patient status (including, but not limited to , survival 
status ) may be obtained by site staff via phone, email, or mail. 
5.5.2 Discontinuation from the Study  
A patient may be discontinued from the study for any of the following reasons: 
• Withdrawal of consent 
• Investigator/Sponsor decision 
• Death  
• Loss to follow-up ( Section  5.5.3) 
• Study completion 
 
If a patient withdraws informed consent  for the study, no additional study data will be collected. 
The Sponsor may continue to use previously collected medical research dat a prior to the 
withdrawal consistent with the original authorization.  
The study may be terminated at any time, for any reason, by the Spons or. Patients still receiving 
study drug should have an EOT visit as described in Section  4.2.3 and Schedule of Events 
(SoE) ( Table  1). 
5.5.3 Loss to Follow -up 
Patients who fail to return for protocol follow -up are to be contacted by the investigative site.  
Following a minimum of two documented unsuccessful telephone calls, the i nvestigative site 
should send a registered letter to the patient in a final attempt to ensure protocol compliance.  
5.6 Patient Replacements  
No patients will be replaced . 
ADC Therapeutics  Camidanlumab tesirine (ADCT -301) 
Final ADCT -301-201 Clinical Protocol  Protocol Amendment 5 
Date of Protocol Amendment 5: 16 February 2022  Page 38 of 87 6 Treatment  
6.1 Study Drug  
Camidanlumab tesirine  will be provided as a lyophilized white to off -white powder in 2 mL 
glass vials (5  mg camidanlumab tesirine per vial) and stored at 2 °C to 8°C. The lyophilized 
camidanlumab tesirine is formulated in 20  mM histidine, 175 mM sucrose, and 
0.04% polysorbate 20, at pH 6.0. Prior to use, the study drug is reconstituted with 1.2 mL of 
sterile water for injection to deliver 1 .0 mL at a concentration of 5 mg/mL . After reconstitution , 
the vial should be  gently swirled  (do not shake the vial)  to ensure complete dissolution and 
homogeneity, and visually inspected  prior to use. Sterile w ater for injection is to be provided 
by study sites. 
Additional study drug description is included in the pharmacy manual. 
6.2 Management of Clinical Supplies  
Detailed instructions regarding study drug shipment, handling, storage, prepa ration , and 
administration  are included  in the pharmacy manual. 
6.2.1 Packaging and Storage  
The study drug will be supplied by the Sponsor  through the designated packaging, labeling, 
and distribution center.  All study drugs must be stored according to the pharmacy manual, in a secure area.  
The lyophilized formulation of  camidanlumab tesirine should be protected from long- term 
exposure to light and stored refrigerated (2°C to 8°C ). Light protection is not required for dose 
preparation and during administration of the diluted drug in the IV bag. 
6.2.2 Preparation and Administration  
The study drug solution at a concentration of 5  mg/mL will be the basis for the preparation of 
the infusion solution. The amount of the product to be diluted will depend on the dose level 
and the body mass of the patient. Of note, a cap on the administered dose is to be applied for 
patients with a body mass index ≥35 kg/m2. Additional details are included in the  pharmacy 
manual. Administration of camidanlumab tesirine will be performed by the Investigator or a qualified 
designee according to the pharmacy manual. Camidanlumab tesirine  is administered as a 30-minute intravenous ( IV) infusion on Day 1 of 
each cycle.  
Variations in infusion times due to minor differences in IV bag overfill/underfill and the 
institution’s procedure for flushing chemotherapy lines will not result in protocol deviation. 
ADC Therapeutics  Camidanlumab tesirine (ADCT -301) 
Final ADCT -301-201 Clinical Protocol  Protocol Amendment 5 
Date of Protocol Amendment 5: 16 February 2022  Page 39 of 87 Extravasation of camidanlumab tesirine may be associated with local i rritation, swelling, pain, 
or tissue damage. The IV infusion site should be monitored for signs of IV infiltration or drug 
extravasation, and patients should be instructed to report immediately any signs of  IV 
infiltration or drug extravasation during or a fter the infusion. Suspected extravasation of 
camidanlumab tesirine should be managed according to institutional protocol for management of extravasation of cytotoxic chemotherapy. 
For patients who have a central line, administration of camidanlumab tesirine via this central 
line should be considered. 
6.2.3 Accountability  
The Investigator or designee will maintain accurate records of receipt of all study drugs, including dates of receipt. In addition, accurate records will be kept regarding when and how much study drug is dispensed and used by each patient in the study. Reasons for departure from the expected dispensing regimen must also be recorded. All study drugs will be reconciled and retained or destroyed according to applicable regulations. 
6.3 Camidanlumab Tesi rine Dosing  
Camidanlumab tesirine  will be administered at a dose of 45 µg/kg Q3W  for 2 cycles, 
then 30 µg/kg for subsequent cycles. 
Refer to Section  6.7 f or premedication and supportive care. 
6.4 Dose Delays and Modifications 
The Investigator may suspend camidanlumab tesirine dosing for up to 21 days , for any patient 
who experiences any toxicity of any grade. Resumption of dosing with camidanlumab tesirine after any suspension, even when longer than 
21 days, is at the discretion of the Investigator, on assessment of the patient’s clinical condition and whether or not the patient is deriving potenti al clinical benefit from treatment with 
camidanlumab tesirine.  
The Investigator may also suspend camidanlumab tesirine dosing for any patient scheduled for HSCT  in the near future , and resumption of dosing is only allowed if the patient has not 
received in the meantime any chemotherapy -based mobilization/conditioning therapy or 
HSCT . 
Management of toxicities, when considered to be at least possibly related  to camidanlumab 
tesirine,  must be performed according to: 
• Section  6.4.1 for general events (i.e., not specified in the below  sections ), 
• Section  6.4.2 for specific non-hematologic events, 
• Section  6.4.3 for specific hematologic events, 
• Section  6.4.4 for specific neurologic events, 
ADC Therapeutics  Camidanlumab tesirine (ADCT -301) 
Final ADCT -301-201 Clinical Protocol  Protocol Amendment 5 
Date of Protocol Amendment 5: 16 February 2022  Page 40 of 87 • Section  6.4.5 for specific skin events.  
 
6.4.1 Guidelines for Dose Modification: General  
AE Grade  Camidanlumab Tesirine Management Guideline  
1/2 No dose adjustment is required.  
3/4 First Occurrence:  
• Hold camidanlumab tesirine until improvement to ≤  Grade 1 or Baseline.  
• If improvement to ≤  Grade 1 or Baseline occurs prior to the next scheduled dose, 
proceed with the originally planned camidanlumab tesirine dose level. 
• If improvement to ≤  Grade 1 or Baseline occurs > 21 days from the last scheduled 
(but missed) camidanlumab tesirine dose, continue camidanlumab tesirine and 
reduce from 45 to 30 µg/kg or from 30 to 20 µg/kg . 
Second Occurrence:  
• Hold camidanlumab tesirine until improvement to ≤  Grade 1 or Baseline, reduce 
from 45 to 30  µg/kg or from 30 to 20 µg/kg. 
Third Occurrence:  
Permanently discontinue camidanlumab tesirine.  
 
ADC Therapeutics  Camidanlumab tesirine (ADCT -301) 
Final ADCT -301-201 Clinical Protocol  Protocol Amendment 5 
Date of Protocol Amendment 5: 16 February 2022  Page 41 of 87 6.4.2 Guidelines for Dose Modification: Specific Non-hematologic  
Toxicities  
Adverse Event  Grade  Camidanlumab Tesirine Management Guideline  
Infusion -related  
reactions  
 1 
 The infusion rate may be decreased or temporarily interrupted 
to permit resolution of the event.  If the total time for dilution 
into the IV bag and infusion takes longer than 4 hours, the 
remaining solution of camidanlumab tesirine will be discarded 
and the dosing will continue with the assigned dose at the next scheduled dosing visit . 
Please refer to Section  6.7.3  for treatment recommendation . 
2 Interrupt camidanlumab tesirine  infusion to permit resolution 
of the event. If the event resolves within the total time of 
4 hours after dilution into the IV bag and infusion time , resume 
camidanlumab tesirine  infusion at 50% of the prior infusion 
rate, still not exceeding the total of 4 hours after infusion has 
restarted.  
If the resolution takes longer than  the total 4 hours,  the 
remaining solution of camidanlum ab tesirine will be 
discarded, and the dosing will continue with the assigned dose at the next scheduled dosing visit at 50% of  the prior infusion 
rate. 
Please refer to Section  6.7.3  for treatment recommendation.  
3 Permanently discontinue camidanlumab tesirine. However, if 
the AE resolves within 24  hours after onset (with or without 
clinical management), dosing may continue with the assigned dose at the next scheduled dosing visit at 50% of the prior infusion rate.  
Please refer to Section  6.7.3  for treatment recommendation.  
4 Permanently discontinue camidanlumab tesirine . 
AST , ALT , or GGT 
abnormalities  
 or 
 Edema  
 or 
 Effusion   
 2/3 
First Occurrence:  
• Hold camidanlumab tesirine until improve ment to 
≤ Grade 1 or Baseline.   
• If improvement to ≤  Grade 1 or Baseline occurs prior to 
the next scheduled dose, proceed with the originally 
planned camidanlumab tesirine dose level. 
• If improvement to ≤  Grade 1 or Baseline occurs > 21 days 
from the last scheduled (but missed) camidanlumab 
tesirine dose, reduce from 45 to 30 µg/kg or from 30 to 
20 µg/kg. 
Second Occurrence:  
• Hold camidanlumab tesirine until improvement to 
≤ Grade 1 or Baseline.  
• If improvement to ≤  Grade 1 or Baseline occurs, reduce 
from 45 to 30  µg/kg or from 30 to 20 µg/kg. 
ADC Therapeutics  Camidanlumab tesirine (ADCT -301) 
Final ADCT -301-201 Clinical Protocol  Protocol Amendment 5 
Date of Protocol Amendment 5: 16 February 2022  Page 42 of 87 Adverse Event  Grade  Camidanlumab Tesirine Management Guideline  
Third Occurrence:  
Permanently discontinue camidanlumab tesirine. 
4 First Occurrence:  
•Hold camidanlumab tesirine until improve ment to
≤ Grade 1 or Baseline.
•If improvement to ≤  Grade 1 or Baseline occurs, continue
camidanlumab tesirine and reduce from 45 to 30 µg/kg or
from 30 to 20 µg/kg.
Second Occurrence:  
Permanently discontinue camidanlumab tesirine. 
Hy’s law ( AST and/or 
ALT > 3 × ULN and 
bilirubin > 2 × ULN)  - Permanently discontinue camidanlumab tesirine.  
Hy’s law defined as: AST and/or ALT > 3 × ULN and 
bilirubin  > 2 × ULN, and without initial findings of cholestasis 
(ALP activity < 2 × ULN) and no other reason that could 
explain the combination of increased transaminases and serum total bilirubin, such as viral hepatitis A, B, or C, preexisting or 
acute liver disease, or another drug capable of causing the 
observed injury.  
Autoimmune t oxicities  
(e.g., hyperthyroidism, 
hypothyroidism, hepatitis, other 
endocrinopathies)  ≥ 1 Need to be followed at least weekly to quickly detect 
deterioration and modify dosing as per general 
recommendations in Section  6.4.1  (can be done by telephone 
unless symptoms worsen).  
Consider using ASCO guidelines  for management of immune -
mediated toxicities  (Brahmer , 2018), or local guidelines.  
Specific guidelines for management of hyperthyroidism, 
hypothyroidism , and hepatitis are provided in the 
Appendix 13.5. 
Selected Types of 
Infection: HSV1, HSV2, VZV, EBV, 
CMV, measles, 
Influenza A, Zika virus, Chikungunya virus, mycoplasma pneumonia, Campylobacter jejuni, 
enterovirus D68 , 
or 
SARS -CoV-2 . Any 
Grade  No dose adjustment is required ; however , hold camidanlumab 
tesirine . Re-dosing must be delayed so that there is at least a 
4-week window between symptom resolution and the next
dose of camidanlumab tesirine.
If there is suspicion that a patient may have contracted the 
coronavirus disease COVID- 19 (e.g., recent contacts with 
persons who tested positive and/or recent symptoms of 
respiratory tract infection and/or recent loss of sm ell and/or 
taste), a pathogen-directed SARS -CoV -2 test, such as 
polymeras e chain reaction (PCR), should be performed. If the 
patient tests positive, a repeat test should be conducted 7 to 
14 days later. If the patient repeatedly tests positive without 
having developed symptoms, dosing may proceed at the 
discretion of the Investigator.  
ADC Therapeutics  Camidanlumab tesirine (ADCT -301) 
Final ADCT -301-201 Clinical Protocol  Protocol Amendment 5 
Date of Protocol Amendment 5: 16 February 2022  Page 43 of 87 6.4.3 Guidelines for Dose Modification: Specific Hematologic Toxicities 
Consider use of granulocyte colony -stimulating factor (G -CSF) as per institutional guidelines 
or as per American Society of Clinical Oncology (ASCO) guidelines for neutropenia/febrile 
neutropenia. 
For anemia, consider use of erythropoietin as per institutional guidelines. If a patient experiences hematologic toxicity of ≥ Grade  3 neutropenia or thrombocytopenia, 
camidanlumab tesirine must be held until the toxicity resolves to ≤ Grade  2. 
6.4.4 Guidelines for Dose Modification: Specific Neurologic Toxicities 
Patients experiencing any new neurological toxicities  and/or new onset of pain refractory to 
common pain medications  ≥ Grade 1, not explained by previous medical history, that could be 
linked to or may be an early indicator of polyradiculopathy/GBS, such as ascending (bilateral) 
sensory loss or motor weakness, need to be immediately evaluated by a neurologist and dosing of camidanlumab tesirine  must be held until polyradiculopathy/GBS is ruled out. Please refer 
to Section  6.7.5 for management of polyradiculopathy/GBS, especially for the 
recommendation of prompt initiation of therapy upon reasonable suspicion of polyradiculopathy/GBS. Should further clinical, radiologic, or laboratory evidence support the 
diagnosis of polyradiculopathy/GBS with L evel 1 diagnostic certainty ( Section  6.7.5 and 
Appendix 13.2), treatment with camidanlumab tesirine must be permanently discontinued.  
Patients with ≥  Grade 3 neurologic toxicities defined as peripheral sensory and peripheral 
motor neuropathies and not explained by previous medical history must have treatment with 
camidanlumab tesirine permanently discontinued. Other new neurological findings not explained by previous medical history with an increase of  
≥ 1 Gr ade over B aseline will result in dose delay; dosing may be resumed after resolution to 
Baseline, at the I nvestigator’s discretion. The patient must be carefully monitored at least 
weekly until such resolution (can be done by telephone unless symptoms worsen). 
ADC Therapeutics  Camidanlumab tesirine (ADCT -301) 
Final ADCT -301-201 Clinical Protocol  Protocol Amendment 5 
Date of Protocol Amendment 5: 16 February 2022  Page 44 of 87 6.4.5 Guidelines for Dose Modification: Specific Skin Toxicities  
Adverse Event  Grade  Camidanlumab Tesirine Management Guideline  
Maculopapular rash 
 
or 
 
Photosensitivity 
rash  
 
or 
 Pruritus  
 or  
 
Xerosis 
 or  
 Hyperpigmentation  
 1 
No dose adjustment is required and monitor for change in 
severity.  
Topical treatment to affected areas is indicated:  
- maculopapular rash, photosensitivity rash, or pruritus: 
high potency topical steroid cream (e.g., clobetasol 
propionate 0.05%, halobetasol propionate 0.05%)  
- xerosis or hyperpigmentation: consider ammonium lactate 
12% or urea 20% BID.  
Reassessment every 2 weeks is indicated (either by healthcare 
professional or patient self -report). 
2 
 No dose adjustment is required and monitor for change in 
severity.  
Topical treatment to affected areas is indicated:  
- maculopapular rash or photosensitivity rash: high potency topical steroid cream (e.g., clobetasol propionate 0.05%, halobetasol propionate 0.05%) . 
- pruritus: high potency topical steroid cream and consider 
oral antipruritic (e.g., hydroxyzine, gabapentin, or 
pregabalin).  
- xerosis or hyperpigmentation: consider ammonium lactate 
12% or urea 20% BID.  
Reassessment every 2 weeks is indicated (either by healthcare professional or patient self -report). 
In case these Grade 2 rashes become intolerable, Grade 3 
recommendations may be applied.  
3 Hold camidanlumab tesirine until improvement to ≤ Grade  1 or 
Baseline and consider dermatology consult. 
Topical treatment to affected areas is indicated  and consider 
systemic corticosteroid treatment  e.g., prednisone 0.5 mg/kg for 
10 days :  
- maculopapular rash or photosensitivity rash: high potency 
topical steroid cream (e.g., clobetasol propionate 0.05%, 
halobetasol propionate 0.05%) and consider prednisone 
0.5 mg/kg for 10 days.  
- pruritus: high potency topical steroid cream 
(e.g., clobetasol propionate 0.05%, halobetasol 
propionate 0.05%) and consider oral antipruritic (e.g., 
hydroxyzine, gabapentin, or pregabalin).  
- xerosis or hyperpigmentation: consider ammonium lactate 
12% or urea 20% BID; and triamcinolone 0.1% cream 
BID. 
ADC Therapeutics  Camidanlumab tesirine (ADCT -301) 
Final ADCT -301-201 Clinical Protocol  Protocol Amendment 5 
Date of Protocol Amendment 5: 16 February 2022  Page 45 of 87 Adverse Event  Grade  Camidanlumab Tesirine Management Guideline  
Reassessment every 2 weeks is indicated (either by healthcare 
professional or patient self -report); if reactions do not improve, 
then:  
First Occurrence:  
• If improvement to ≤  Grade 1 or Baseline occurs prior to the 
next scheduled dose, proceed with the originally planned 
camidanlumab tesirine dose level . 
• If improvement to ≤  Grade 1 or Baseline occurs  
> 21 days from the last scheduled (but missed) 
camidanlumab tesirine dose, reduce from 45 to 30 µg/kg or 
from 30 to 20 µg/kg.  
Second Occurrence:  
• If improvement to ≤  Grade 1 or Baseline occurs, reduce 
from 45 to 30 µg/kg or from 30 to 20 µg/kg.  
Third Occurrence:  
Permanently discontinue camidanlumab tesirine. 
4 Hold camidanlumab tesirine until improvement to ≤ Grade  1 or 
Baseline and consider dermatology consult. 
Topical treatment to affected areas is indicated  and consider 
systemic corticosteroid treatment , e.g., prednisone 0.5 mg/kg for 
10 days :  
- maculopapular rash or photosensitivity rash: high potency topical steroid cream (e.g., clobetasol propionate 0.05%, halobetasol propionate 0.05%) and consider prednisone 
0.5 mg/kg for 10 days.  
- pruritus: high potency topical steroid cream 
(e.g., clobetasol propionate 0.05%, halobetasol 
propionate 0.05%) and consider oral antipruritic (e.g., 
hydroxyzine, gabapentin, or pregabalin).  
- xerosis or hyperpigmentation: c onsider ammonium lactate 
12% or urea 20% BID; and triamcinolone 0.1% cream 
BID. 
Reassessment every 2 weeks is indicated (either by healthcare 
professional or patient self -report); if reactions do not improve, 
then:  
First Occurrence:  
• If improvement to ≤  Grade 1 or Baseline occurs, continue 
camidanlumab tesirine and reduce from 45 to 30 µg/kg or 
from 30 to 20 µg/kg.  
Second Occurrence:  
Permanently discontinue camidanlumab tesirine. 
ADC Therapeutics  Camidanlumab tesirine (ADCT -301) 
Final ADCT -301-201 Clinical Protocol  Protocol Amendment 5 
Date of Protocol Amendment 5: 16 February 2022  Page 46 of 87 Adverse Event  Grade  Camidanlumab Tesirine Management Guideline  
Blistering rash  1 No dose adjustment is required and monitor for change in 
severity. Consider dermatology consult  
Topical treatment to affected areas is indicated, e.g., silvadene 
1% cream BID and consider laboratory testing for blistering 
disorder (VZV/HSV and bacterial infection; bullous 
pemphigoid; pemphigus).  
Reassessment every 2 weeks is indicated (either by healthcare professional or patient self -report). 
 2/3 Hold camidanlumab tesirine until improvement to ≤ Grade 1 or Baseline and consider dermatology and wound care consult.  
Topical treatment to affected areas is indicated,  e.g., silvadene 
1% cream BID , and  consider laboratory testing for blistering 
disorder (VZV/HSV and bacterial infection; bullous 
pemphigoid; pemphigus)  and consider systemic corticosteroid 
treatment, e.g., prednisone 0.5 mg/kg for 10 days . 
Reassessment every 2 weeks is indicated (either by healthcare professional or patient self -report); if reactions do not improve, 
then:  
First Occurrence:  
• If improvement to ≤  Grade 1 or Baseline occurs prior to the 
next scheduled dose, proceed with the originally planned 
camidanlumab tesirine dose level.  
• If improvement to ≤  Grade 1 or Baseline occurs > 21 days 
from the last scheduled (but missed) camidanlumab tesirine dose, continue camidanlumab tesirine and reduce from 45 to 30 µg/kg or from 30 to 20 µg/kg. 
Second  Occurrence:  
• If improvement to ≤  Grade 1 or Baseline occurs, reduce 
from 45 to 30 µg/kg or from 30 to 20 µg/kg.  
Third Occurrence:  
Permanently discontinue camidanlumab tesirine. 
 4 Hold camidanlumab tesirine until improvement to ≤ Grade 1 or Baseline and consider dermatology consult.  
Topical treatment to affected areas is indicated, e.g., silvadene 1% cream BID, and consider 
laboratory testing for blistering 
disorder (VZV/HSV and bacterial infection; bullous 
pemphigoid; pemphigus)  and consider systemic corticosteroid 
treatment, e.g., prednisone 0.5 mg/kg for 10 days . 
Reassessment every 2 weeks is indicated (either by healthcare professional or patient self -report); if reactions do not improve, 
then:  
First Occurrence:  
• If improvement to ≤  Grade  1 or Baseline occurs, continue 
camidanlumab tesirine and reduce from 45 to 30 µg/kg or 
from 30 to 20 µg/kg.  
ADC Therapeutics  Camidanlumab tesirine (ADCT -301) 
Final ADCT -301-201 Clinical Protocol  Protocol Amendment 5 
Date of Protocol Amendment 5: 16 February 2022  Page 47 of 87 Adverse Event  Grade  Camidanlumab Tesirine Management Guideline  
Second Occurrence:  
Permanently discontinue camidanlumab tesirine. 
 
6.5 Overdose Management 
An overdose is any dose of study drug given to a patient that exceeds the maximum dose 
described in the protocol  by 15% or more . Any overdose, with or without associated AEs, must 
be promptly (i.e., within 24 hours after the time site personnel first learn about the event) 
reported to the Sponsor. 
There are no data available to determine what the effects of overdose are and whether they can 
be reversed. Symptomatic treatment and standard supportive care measures for the management of any observed toxicity should be applied. 
If feasible, a sample for PK analysis should be taken as close as possible to the overdose event.  
6.6 Treatment Compliance 
Administration of the study drug will be performed by the Investigator or a qualified designee; 
therefore, compliance will be verified by the study drug administration information. 
6.7 Premedication and Supportive Care 
6.7.1 Premedication  
Unless contraindicated, administer dexamethasone 4  mg orally  twice daily ( BID) , or 
equivalent, the day before camidanlumab tesirine administration (if possible), the day of 
camidanlumab tesirine administration (give at least 2  hours prior to administration when not 
given the day before; otherwise any time prior to administration), and the day after 
camidanlumab tesirine  administration.  
[For Italy Sites Only: Prednisone 25 mg BID is the only equivalent to the dexa methasone 
4 mg BID dose permitted as alternative premedication . The dosing schedule of dexamethasone 
and prednisone is the same .] 
Patients who experience an infusion- related hypersensitivity reaction  will receive the 
alternative prem edication regimen specified in  Section  6.7.3. 
6.7.2 Treatment of Edema and Pleural Effusion  
Spironolactone at standard doses should be administered for patients with weight gain greater 
than 1 kg from C1D1, new or worsening edema, and/or new or worsening pleural effusion. The dose of spironolactone may be titrated as clinically indicated. Additional diuretic support may be added if there is further increase in weight, edema, or pleural effusion. 
Additionally,  patients should be advised to monitor their weight on a daily basis,  at around the 
same time ( preferably in the morning) , and to notify the study site if they gain > 1 kg 
(2.2 pounds) over B aseline.  
ADC Therapeutics  Camidanlumab tesirine (ADCT -301) 
Final ADCT -301-201 Clinical Protocol  Protocol Amendment 5 
Date of Protocol Amendment 5: 16 February 2022  Page 48 of 87 6.7.3 Treatment and Prophylaxis of Infusion- Related  Hypersensitivity  
Reactions 
Medications for the treatment of severe hypersensitivity reactions, including anaphylaxis, 
should be available for immediate use and may be administered according to site standard treatment protocols.  
Any patient who experiences an infusion- related hypersensitivity  reaction should receive 
prophylactic treatment in subsequent cycles according to the guidelines below  or per 
institutional standard of care : 
• On Day  1 of each cycle, patients will be instructed to take dexamethasone 20 mg orally  
12 and 6 hours before the start of the camidanlumab tesirine  infusion. When necessary, 
12 and 6 hours before the first infusion may be defined as “immediately before sleeping ” 
and “ immediately after waking up. ” 
• On Day  1 of each cycle, patients will be given diphenhydramine hydrochloride 50 mg  IV 
30 minutes before the start of the camidanlumab tesirine  infusion. 
• On Day  1 of each cycle, patients will be given ranitidine (or equivalent) 50 mg  IV 
30 minutes before the start  of the camidanlumab tesirine  infusion. 
• For 2  days following administration of camidanlumab tesirine on Day 1, patients are to 
take dexamethasone 4  mg orally  BID. 
 
6.7.4 Consideration for Skin Toxicity 
Skin toxicity has been  reported in patients receiving camidanlumab tesirine for hematologic 
malignancies. Often, t he toxicities manifested as rash were  reported in sun expos ed areas; it is 
therefore recommended that precautions are taken  to avoid exposure of skin to sunlight , even 
through glass  (e.g., use of sun protective clothing and sunglasses, sunscreen with a sun 
protection factor  ≥ 30 applied every 2 hours , avoidance of  being outside with no protection). 
Also, fragrance- free detergents and soaps are recommended . 
Consideration should be given to corticosteroid therapy in patients who develop clinically 
significant skin toxicity  (guidelines for dose modification in Section  6.4.5).  
Photographs of skin toxicity may be taken for documentation purposes at the discretion of the Investigator provided the patient has given consent.  
ADC Therapeutics  Camidanlumab tesirine (ADCT -301) 
Final ADCT -301-201 Clinical Protocol  Protocol Amendment 5 
Date of Protocol Amendment 5: 16 February 2022  Page 49 of 87 6.7.5 Diagnostic, Work -up, and Management of Polyradiculopathy/ 
Guillain -Barré Syndrome  
It is strongly recommended starting prompt management of polyradiculopathy/GBS  with either  
intravenous immunoglobulin ( IVIg ) 0.4 g/kg/day for 5 days or plasma exchange (PLEX) once 
diagnosis of polyradiculopathy/GBS  has been considered by a neurologist; this c ould be at 
CTCAE Grade  2 symptoms  for neuropathy or Score 1 as per GBS disability scale 
(Appendix 13.3).  It has to be considered that manifestati on of polyneuropathy can be variable.  
Diagnostic workup should include: 
• Neurology consultation 
• Magnetic resonance imaging ( MRI ) spine with and without contrast to rule out 
compressive lesion and evaluate for nerve root enhancement or thickening 
• Electrodiagnostic studies (nerve conduction studies) 
• Serologic test for SARS -CoV-2 (Alberti, 2020; Toscano , 2020; Zhao , 2020) 
• Pulmonary function tests  
• Lumbar puncture: cerebrospinal fluid ( CSF) typically has albuminocytologic 
dissociation , i.e., protein elevation disproportionate to white blood cells ( WBC s—
although note that CSF WBC s are often elevated in GBS associated with immune 
checkpoint inhibitors) 
• Serum antibody testing for GBS (ganglioside antibodies) when possible 
 
Management includes:  
• IVIg or PLEX as above  
• If IVIg and/or PLEX do not result in improvement, consider using steroids ( Gu, 2017)  
• Admission to inpatient unit with capability for r apid transfer to intensive care unit -level 
monitoring 
• Frequent focused neurological examination (at least twice daily) 
• Frequent pulmonary function monitoring 
• Monitoring for autonomic dysfunction 
• Non-opioid management of neuropathic pain  
• Treatment of const ipation/ileus  
• Anticoagulation 
• Physical therapy  
 
ADC Therapeutics  Camidanlumab tesirine (ADCT -301) 
Final ADCT -301-201 Clinical Protocol  Protocol Amendment 5 
Date of Protocol Amendment 5: 16 February 2022  Page 50 of 87 6.7.6 Other  Supportive Care 
Although the study patient population has a low risk for development of tumor lysis syndrome 
(TLS) compared to patients with acute disease ( Cairo , 2010), patients should be observed for 
development of TLS and treated according to site standard treatment protocols. 
As testing  in animals  showed testicular toxicity (atrophy with reduced spermatogenesis), 
male  patients are advised to consider cryopreservation of sperm prior to treatment with 
camidanlumab tesirine , where applicable.  
The iDSMB recommended VZV prophylaxis  according to institutional guidelines for all  
patients enrolled in this study (whether already receiving camidanlumab tesirine or newly 
enrolled). 
6.8 Concomitant Medications and Procedures  
Medications (except for the study drug)  and procedures will be recorded in the eCRF starting 
from the  ICF signature date or from 14 days prior to C1D1, whichever is earlier , and continuing 
until 30 days after last dose of study drug. 
6.8.1 Permitted During Study  
Medication s or procedure s for the clinical care of the patient, including management of AEs, 
are permitted during the study, except for those listed in  Section  6.8.2.  
Hematopoietic growth factors  are permitted  as per ASCO guidelines ( Smith , 2006).  
6.8.2 Prohibited During Study  
• Other anticancer therapy  during the Treatment Period  (including palliative radiotherapy) , 
with the exception of hormonal therapy for maintenance treatment of breast and prostate 
cancer.  
• Other investigational agents during the Treatment Period . 
• Live vaccines  during the Treatment Period  and for 3 months after  last dose of study drug. 
 
ADC Therapeutics  Camidanlumab tesirine (ADCT -301) 
Final ADCT -301-201 Clinical Protocol  Protocol Amendment 5 
Date of Protocol Amendment 5: 16 February 2022  Page 51 of 87 7 Study Assessments and Procedures 
7.1 Informed Consent 
Informed consent, as documented by a signed and dated ICF, must be obtained prior to 
performing any study procedures. Results (e.g., from laboratory tests or radiographic evaluations, etc.) obtained prior to the date of informed consent but within the allowed timeframe for screening may be used for determination of patient eligibility only if obtained as part of standard care.  For additional details, please refer to Section  11.3. 
7.2 Demographics and Baseline Characteristics  
These assessments include:  
• Demographic information such as age, gender, ethnicity, and race (to the extent allowed 
by local regulations).  
• Cancer medical history, which includes a complete history of all surgeries and significant diagnoses, and all cancer treatment, including surgery, radiation therapy, chemotherapy, etc. 
• Immune -related adverse events of prior checkpoint inhibitors. 
• Any other relevant medical history . Importantly, according to the iDSMB 
recommendation patients with signs or symptoms of Grade  2 neuropathy should be 
examined by a neurologist at Screening. 
• Collection of information on prior medications used from ICF signature date or at least within 14 days prior to camidanlumab administration, whichever is earlier . 
 
7.3 Efficacy Assessments  
Disease assessments will occur as per SoE ( Table  1) until progression .  
Screening (Baseline) imaging must be performed within 4 weeks prior to C1D1. 
During the treatment period, imaging will be performed 6 weeks and 12  weeks after C1D1, 
then every 9 weeks until EOT. Week  6 imaging should be performed within 1 week prior to 
C3D1 and Week 12 imaging should be performed within 1  week prior to C5D1. All other 
imaging should be performed within ±2 weeks of the scheduled time point. 
Disease assessments should take place at the timepoints specified even if study drug dosing is delayed. 
During the follow -up period, patients who discontinued study drug for reasons other than 
disease progression or initiation of other anti -cancer therapy will have imag ing performed 
every 12 (± 2) weeks until 1 year from EOT, then every 6 months until disease progression, up 
to 3 years from EOT ; when patients discontinue the study drug because they are planned to 
undergo a HSCT  or to receive  CAR- T therapy, imaging will continue the same way . 
Moreover, HSCT information such as but not limited to type  of HSCT , conditioning therapy 
ADC Therapeutics  Camidanlumab tesirine (ADCT -301) 
Final ADCT -301-201 Clinical Protocol  Protocol Amendment 5 
Date of Protocol Amendment 5: 16 February 2022  Page 52 of 87 should be recorded in the eCRF. Likewise for CAR- T therapy, the type of CAR -T used 
including conditioning therapy should be recorded in the eCRF. 
If a scan has been performed within 6 weeks of EOT, it does not need to be repeated at EOT. Additional disease assessments may be obtained , if clinically indicated. 
Positron emission tomography- computed tomography (PET -CT) of the neck/chest/abdomen/  
pelvis and other areas of known disease or newly suspected disease, as well as a clinical 
examination for lymphoma, will be performed. If it is known that the tumor is tracer-avid, the baseline CT as part of the PET -CT does not have to be performed with contra st medium; 
however, if the tumor is not tracer -avid, diagnostic CT should be used and contrast medium 
considered, however  patients who have a contraindication to CT IV contrast medium should 
have MRI  examinations performed instead. The assessment method determined to identify 
sites of disease at B aseline (i.e., PET -CT, CT, MRI) should be used for all subsequent 
assessments.  
Patients whose tumor is not PET- avid should have a bone marrow biopsy as part of their 
baseline staging and disease assessment if cli nically appropriate.  
The patient’s response to treatment will be determined according to the 2014 Lugano Classification Criteria (Appendix 13.4) as CR, PR, stable disease (SD), or progressive disease 
(PD).  Upon indication of clinical progression (non- radiographic), a radiographic disease 
assessment to confirm the PD is expected , if clinically indicated , in order to ensure appropriate 
data collection toward the primary endpoint of this protocol. 
Images will be obtained according to local site imaging requirements and will be submitted for 
a central/independent review. Central imaging review will be performed using two blinded 
independent reviewers with  adjudication by a third blinded independent reviewer in cases of 
discordance. Submission instructions for the central/independent review will be provided in a 
separate manual.  
7.4 Safety Assessments   
Safety will be assessed  based on the procedures in the subsection below. AEs/SAEs collection 
and reporting is described in Section  8. 
Unless otherwise specified, all safety assessments on dosing days wi ll be done prior to study 
drug administration. 
7.4.1 Physical Examination  
Physical examinations will be performed according to institutional standards and will include 
whole body skin examination.  
Physical examinations will also include a neurological examination of strength, sensation, and 
deep tendon reflexes . In addition, patients will be asked whether they are  or have been 
experiencing subjective neurologic symptoms  (at screening or since the last visit), such as 
blurred vision, muscle weakness, or paresthesia, and the response must be documented in the 
ADC Therapeutics  Camidanlumab tesirine (ADCT -301) 
Final ADCT -301-201 Clinical Protocol  Protocol Amendment 5 
Date of Protocol Amendment 5: 16 February 2022  Page 53 of 87 CRF ; refer to Section  6.4.4 for dose modification due to specific neurologic toxicities and 
Section  6.7.5 for details on polyradiculopathy/GBS management. This examination does not 
need to be conducted by a neurologist. Neurologic consultation needs to  be obtained for any 
abnormal findings not explained by previous medical history (e.g., a patient with left sided 
weakness known to be a result of a previous cerebrovascular accident would not need to see a neurologist as part of this study) that could be linked to or may be an early indicator of polyradiculopathy/GBS, such as ascending (bilateral) sensory loss , motor weakness, or new 
onset of pain, which is refrac tory to common pain medications and  with or without any 
additional neurological deficiencies . 
The examination must include a determination if the patient has had any recent infection. 
At the discretion of the Investigator, evaluation of any reported infection must be conducted to 
rule out infection with a microorganism that may be associated with autoimmune or neurological disease(s) as specified in the exclusion criteria ( Section  5.2) and Section  7.4.5. 
7.4.2 ECOG P erformance Status  
ECOG performance status grades are presented in Appendix 13.1 and will be captured as per 
SoE ( Table  1). 
7.4.3 Height and Weight 
Height and weight will be measured  as per SoE ( Table  1). 
Additiona l measurements will be performed if clinically indicated.  
Patient s should monitor their weight at home  to detect potential  edema/effusions. 
Refer  to Section  6.7.2 for further details.  
7.4.4 Vital Signs 
Vital signs will be measured as per SoE ( Table  1). 
Vital signs include the measurements of arterial BP  (systolic and diastolic), heart  rate (HR) , 
respiratory rate, and body temperature  and will be performed according to the institutional 
standards.  
For Day  1 of each cycle, vital signs are to be measured before the start of the camidanlumab 
tesirine  infusion and at the end of infusion (example in Figure  2). 
7.4.5 Laboratory Tests  
Sample s will be collected  at the time points specified as per SoE  (Table  1) and will be analyzed 
locally . Additional sample(s) may be collected and analyzed if clinically indicated. The C1D1 
laboratory test(s) can be waived if the laboratory test(s) for eligibility was done within 3 days of C1D1. 
Hematology : WBC s with 5 -part differential (neutrophils, eosinophils, basophils, lymphocytes, 
and monocytes), platelet count, hemoglobin, and hematocrit. 
ADC Therapeutics  Camidanlumab tesirine (ADCT -301) 
Final ADCT -301-201 Clinical Protocol  Protocol Amendment 5 
Date of Protocol Amendment 5: 16 February 2022  Page 54 of 87 Chemistry:  ALT, AST, GGT, ALP, amylase, lipase, total bilirubin ( conjugated and 
unconjugated bilirubin only when total bilirubin is abnormal), sodium, potassium, chloride, 
phosphorus/phosphate, calcium, magnesium, blood urea nitrogen or urea, carbon 
dioxide/bicarbonate, creatinine, creatine phosphokinase, total protein, albumin, gluc ose, and 
lactate dehydrogenase.  
Coagulation:  partial thromboplastin time (PTT)/activated PTT (aPTT)  and INR . 
Urinalysis : pH, specific gravity, protein, WBC s, red blood cell (RBC s), ketones, glucose, and 
bilirubin. 
Urinalysis may be performed by dipstick. A bnormal findings will be followed up with a 
microscopic evaluation and/or additional assessments as clinically indicated. A microscopic 
evaluation consists at a minimum of WBC and RBC quantitation per high power field, as well as semi -quantit ative assessment of other cells and substances, if present, such as epithelial cells, 
bacteria , and crystals (“few,” “moderate,” “many”). Other evaluations depending on 
microscopic findings may be added. 
Thyroid function tests : Thyroid-s timulating hormone (TSH); reflex free T4 (FT4) and/or free 
triiodothyronine (FT3) , as applicable, only when TSH is abnormal. 
Influenza and SARS -CoV-2:  An influenza test and a pathogen- directed  SARS -CoV -2 test  
(such as PCR ) must be performed and be negative for eligibility purpose s. 
Viral detection: Seropositive patients for, or with prior history of, HIV, HBV, or HCV not 
receiving antiviral therapy at screening will be monitored during the study (not needed if 
seropositivity is only due to vaccination). 
Additional microbiological studies: Pathogens of interest are: HSV1, HSV2, VZV, EBV, 
CMV, measles, Influenza A, Zika virus, Chikungunya virus, mycoplasma pneumonia, Campylobacter jejuni , enterovirus D68 , and 
SARS -CoV-2. 
Patients will be regularly examined and asked whether they have been suffering from or exhibit 
symptoms of an infection during their participation in the trial. If there is a reasonable suspicion 
that such infection could have been caused by one of the pathogens listed above, appropriate microbiological workup must be conducted. See Section  6.4.2 for dose delay recommendation 
upon confirmation of infection by one of these microorganisms. 
If there is suspicion that a patient may have contracted the coronavirus disease COVID -19 (e.g., 
recent contacts with persons who tested positive and/or recent symptoms of respiratory tract 
infection and/or rec ent loss of sm ell and/or taste), a pathogen- directed  SARS -CoV- 2 test, such 
as PCR, should be performed. If the patient tests positive, a repeat test should be conducted 
7 to 14 days later. If the patient repeatedly tests positive without having developed symptoms, dosing may proceed at the discretion of the Investigator. 
ADC Therapeutics  Camidanlumab tesirine (ADCT -301) 
Final ADCT -301-201 Clinical Protocol  Protocol Amendment 5 
Date of Protocol Amendment 5: 16 February 2022  Page 55 of 87 7.4.6 Pregnancy T est 
A highly sensitive β -HCG test in urine or blood β -HCG test will be performed in WOCBP for 
eligibility (see  Section  5.1) and throughout the study as per SoE ( Table  1). 
The C1D1 pre -dose pregnancy test can be waived if the test for eligibility was done within 
7 days of C1D1 . After starting the study drug, the interval between 2 consecutive pregnancy 
tests should be no more than 6 weeks. 
The EOT pregnancy test should be performed ≥ 9.5 months  after the last dose of study drug 
(i.e., end of relevant systemic exposure considering 5 half -lives  plus 6 months for  other than 
aneugenic genotoxic compound).  If the EOT visit is planned less than 9.5 months  after the last 
dose of study drug, the patient will be asked either to come back to the site for a pregnancy test 
or she will be given a pregnancy kit to perform the test at home and the result collected over  
the phone. Both the phone contact and the result of the pregnancy test must be documented on 
source documents at the site. 
If a pregnancy test is positive, the study drug must be held pending confirmat ion. 
If the pregnancy is confirmed, camidanlumab tesir ine treatment  will be discontinued 
permanently for the patient . Refer to  Section  8.6 for the handling of the patient and reporting 
the event.  
7.4.7 ECG  
Three consecutive (also called triplicate ) 12- lead ECGs will be performed at defined 
timepoints throughout the study  as per SoE ( Table  1). Refer to Table  3 for the detailed schedule 
of ECGs.  The ECGs will be performed after the patient is resting for at least 5 min utes. 
At timepoints coinciding with blood sample collection, including PK, ECG s should be taken 
prior to blood collection, and, when applicable, before vital signs measurements  
(example in Figure 2).  If a patient experiences Torsade de Pointes, additional concomitant 
PK samples (i.e.,  unscheduled) should be collected. 
The ECGs will be submitted for a central review. Submission instructions for the central review 
will be provided in a separate manual. Assessments will include determination of heart rate 
and rhythm and the PR, QRS, QT, QTcF, and QTcB intervals. Eligibility and clinical decisions 
may be made based on the local ECG assessment.  
ADC Therapeutics  Camidanlumab tesirine (ADCT -301) 
Final ADCT -301-201 Clinical Protocol  Protocol Amendment 5 
Date of Protocol Amendment 5: 16 February 2022  Page 56 of 87 Table  3 Schedule for Triplicate ECG C ollection  
Cycle  Day ECG t imepoint (window)  
Screening  - Any time within 28 days prior to C1D1  
C1 D1 Predose (preferably within 2 h prior  to start of infusion)  
EOI (within 10 min prior to  EOI) 
Postdose* 4 h (± 15 min)  
D8 Postdose* 168 h (± 48 h; but within 30 min prior to PK sample)  
D15 Postdose* 336 h (± 48 h; but within 30 min prior to PK sample)  
C2 D1 Predose (within 30 min prior to PK sample)  
EOI (within 10 min prior to EOI) 
Postdose* 4 h (± 15 min)  
D8 Postdose* 168 h (± 48 h; but within 30 min prior to PK sample)  
D15 Postdose* 336 h (± 48 h; but within 30 min prior to PK sample)  
C3 and C4  
 D1 Predose (within 30 min prior to PK sample)  
EOI (within 10 min prior to EOI) 
C5, C7 … 
every other cycle  D1 Predose (within 30 min prior to PK sample)  
EOT   Any time (but within 30 min prior to PK sample)  
Unscheduled   Any time  
Abbreviations: C1D1, Cycle 1, Day 1; ECG, electrocardiogram; EOI,  end of infusion; EOT, end of treatment; 
PK, pharmacokinetics . 
* Postdose tim epoint is counted from start of infusion.  
 
ADC Therapeutics  Camidanlumab tesirine (ADCT -301) 
Final ADCT -301-201 Clinical Protocol  Protocol Amendment 5 
Date of Protocol Amendment 5: 16 February 2022  Page 58 of 87 7.5.1 Pharmacokinetics 
The PK profile of camidanlumab tesirine PBD -conjugated antibody, total antibody, and 
unconjugated warhead SG3199 will be assessed in serum by a central laboratory  designated 
by the Sponsor using validated bioanalytical methods. 
Up to 6 mL of whole blood will be collected as per Table  1 and Table  4. Blood should be 
drawn from a vein away from the one used for study drug infusion. The serum PK samples must be stored at ≤  -70°C . Please refer to the laboratory manual for 
detailed  instructions regarding specimen handling and shipment. 
At timepoints coinciding with ECG collection, PK blood collection should occur immediately 
after the end of the ECG recording  and, when applicable, after vital signs  (example in  Figure 2).  
If a patient experiences Torsade de Pointes, concomitant PK samples (e. g., unscheduled) 
should be collected.  
Table  4 Sampling Schedule for PK and ADA 
Cycle  Day PK t imepoint  (window ) ADA time point (window ) 
C1 D1 Predose (preferably within 2 h prior 
to start of infusion)  
EOI (-5 to +10 min)  
Postdose* 4 h (± 10 min)  Predose (preferably within 2 h prior 
to start of infusion)  
 
D8 Postdose* 168 h (± 48 h)  - 
D15 Postdose* 336 h ( ± 48 h)  Postdose* 336 h (± 48 h)  
C2 D1 Predose (within 2  h prior to start of 
infusion)  
EOI ( -5 to +10 min) 
Postdose* 4 h (± 10 min)  Predose (within 2  h prior to start of 
infusion)  
D8 Postdose* 168 h ( ± 48 h)  - 
D15 Postdose* 336 h ( ± 48 h)  - 
C3, C4, C5,  and 
C6 D1 Predose (within 2  h prior to start of 
infusion)  
EOI (-5 to +10 min)  - 
C3, C5, … 
every other cycle  D1 - Predose (within 2 h prior to start of 
infusion)  
C7, C8, … 
every cycle D1 Predose (within 2  h prior to start of 
infusion)  - 
ADC Therapeutics  Camidanlumab tesirine (ADCT -301) 
Final ADCT -301-201 Clinical Protocol  Protocol Amendment 5 
Date of Protocol Amendment 5: 16 February 2022  Page 59 of 87 Cycle  Day PK t imepoint  (window ) ADA time point (window ) 
EOT   At any  time during visit day  At any  time during visit day 
Unscheduled   Any time Any time (if applicable, together 
with PK sample) 
Abbreviations:  ADA,  anti-drug an tibody; EOI, end of infusion; EOT,  end of trea tment; PK,  pharmacokinetics . 
* Postdose timepoint is counted from  start of infusion.  
 
To understand the metabolic disposition of camidanlumab tesirine in humans, samples 
remaining after PK analysis is complete may be pooled among patients for potential metabolite 
identification.   
7.5.2 Immunogenicity 
Detection of ADAs will be  performed by using a screening assay for identification of antibody 
positive samples/patients , a confirmation assay, and titer assessment . 
Up to 6 mL of whole blood will be collected as per Table  1 and Table  4. 
Blood should be drawn from a vein away from the one used for study drug infusion. 
For patients who test positive for ADA, additional ADA sample s will be requested for testing 
every 12 weeks  following the EOT visit until the ADA titer falls to a background level , as long 
as the patient is still on -study. 
The ADA samples must be stored at ≤ -70°C. Please refer to the laboratory manual for detail ed 
instructions regarding specimen handling and shipment. 
7.5.3 Biomarkers  
7.5.3.1  Blood Samples for Biomarkers 
Blood samples for biomarkers analyses will be collected as per SoE ( Table  1) and a more 
detailed presen tation of soluble markers timepoints is provided in Table  5. 
Please refer to the laboratory manual for detailed instructions regarding specimen handling and 
shipment.  
Soluble Biomarkers:  Up to 6 mL of blood for the quantification of immunologically r elevant 
biomarkers (e.g., IL-2, IL-6, IL -8, IL-10, IFNγ, TNFα,  sCD25 , CCL17 ) will be taken  at 
multiple  timepoints . This will include analyses of biomarkers that may be predictive of or  
associated  with  GBS  (at a minimum  on C1D1 and C3D1 predose). 
cfDNA/gDNA:  Up t o 30 mL of whole blood will be taken at multiple timepoints for 
investigating genetic alterations characterizing Hodgkin lymphoma in cfDNA. gDNA will be analyzed to confirm the somatic origin of the genetic alterations  and will be measured at 
predose C1D1 and EOT only. 
ADC Therapeutics  Camidanlumab tesirine (ADCT -301) 
Final ADCT -301-201 Clinical Protocol  Protocol Amendment 5 
Date of Protocol Amendment 5: 16 February 2022  Page 60 of 87 Table  5 Sampling Schedule for Soluble Biom arkers  
Cycle  Day Timepoint (window) 
C1 D1 Predose (preferably within 2 h prior to start of infusion)  
Postdose* 4 h (± 10 min)  
D8 Postdose* 168 h (± 48 h)  
D15 Postdose* 336 h (± 48 h)  
C2 D1 Predose (within 2 h prior to start of infusion)  
Postdose* 4 h (± 10 min)  
D8 Postdose* 168 h (± 48 h)  
D15 Postdose* 336 h (± 48 h)  
C3 D1 Predose (within 2 h prior to start of infusion)  
EOI (within 10 min prior to EOI)  
C5, C7, … 
every other cycle  D1 Predose (within 2 h prior to start of infusion)  
EOT   At any time during visit day  
Follow -up  - 
Unscheduled   Any time (if applicable, together with PK sample)  
Abbreviations: EOT, end of treatment; PK, pharmacokinetics.  
* Postdose timepoint is counted from start of infusion.  
 
7.5.3.2  Tumor T issue  for Biomarkers  
Available tumor tissue will be collected to investigate potential predictive markers of clinical 
response. Any sample since initial diagnosis is acceptable, but if several samples are available, 
the most recent sample is preferred. Tumor tissue (FFPE block preferre d) should be submitted 
once it has been determined that the patient meets all other eligibility criteria and is scheduled to proceed with study drug administration. 
Please refer to the laboratory manual for detail ed instructions regarding specimen handling and 
shipment. 
ADC Therapeutics  Camidanlumab tesirine (ADCT -301) 
Final ADCT -301-201 Clinical Protocol  Protocol Amendment 5 
Date of Protocol Amendment 5: 16 February 2022  Page 61 of 87 7.6 Health- Related Quality of Life (HRQoL) Questionnaires  
7.6.1 EuroQoL- 5 Dimensions- 5 Levels (EQ -5D-5L) 
The EQ -5D- 5L is designed as an international, standardized, generic instrument for describing 
and evaluating QoL (EuroQoL Group, 1990). This questionnaire can be completed by patients 
≥12 years of age. The EQ -5D-5L consists of 2 parts:  
• The descriptive system: QoL is classified according to 5 dimensions: mobility, 
self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension 
comprises 5 levels of perceived problems (e.g., none, slight, moderate, severe, 
extreme).  
• The visual analog scale (VAS): patients are asked to indicate their health state today  on 
a VAS with the endpoints labeled ‘the best health you can imagine’ (score 100) and 
‘the worst health you can imagine’ (score 0). Patients are asked to mark an “X” on the VAS to indicate their own health and then to report the score in a text box. If th ere is a 
discrepancy between where the patient has placed the X and the number he/she has written in the box, the number in the box is to be entered in the CRF together with a comment indicating the discrepancy. 
 
7.6.2 Functional Assessment of Cancer Therapy - L ymphoma (FACT -Lym)  
The FACT -Lym is a lymphoma -specific subscale for the Functional Assessment of Cancer 
Therapy (FACT) questionnaire ( Hlubocky, 2013 ). As this questionnaire has been validated for 
patients ≥18 years old;  therefore , it will not be adminitered to patients <18 years old (age at 
screening). It consists of 15 specific items that are used together with the core 27 -item 
questionnaire FACT -G. The  patient is asked to respond to each item with a score of 0 -4, where 
0 = not at all, 1 = a little bit, 2 = somewhat, 3 = quite a bit, and 4 = very much. A higher score indicates a worse level of QoL.  
 
ADC Therapeutics  Camidanlumab tesirine (ADCT -301) 
Final ADCT -301-201 Clinical Protocol  Protocol Amendment 5 
Date of Protocol Amendment 5: 16 February 2022  Page 62 of 87 8 Adverse Events 
8.1 Definition of Adverse Events , Serious Adverse Events , and Adverse 
Events of Special Interest  
An AE is defined as any untoward medical occurrence in a patient or clinical investigation 
subject administered a pharmaceutical product, which does not necessarily have to have a causal relationship wit h this treatment.  
Test results collected during the study (e.g., laboratory values, physical examination, ECG s, 
etc.) or identified from review of other documents may constitute AEs if deemed clinically significant.  
An SAE is defined as any AE that:  
• results in death.  
• is life threatening.  
• requires inpatient hospitalization or prolongation of existing hospitalization 
(hospitalization for elective procedures or for protocol compliance is not considered an 
SAE).  
• results in persistent or significant disability/incapacity.  
• is a congenital anomaly/birth defect.  
• important medical events that do not meet the preceding criteria but based on 
appropriate medical judgment may jeopardize the patient or may require medical or 
surgical intervention to prevent any of the outcomes listed above. 
 
Adverse Events of Special Interest (AESIs) are significant AEs that are judged to be of special interest because of clinical importance, known class effects, or based on preclinical signals. Events considered to be AESIs are identified in Section  8.1.1. 
8.1.1 Adverse Events of Special Interest  
For this study the following adverse events, irrespe ctive of seriousness and causality, are 
considered AESIs : 
• GBS (including variants such as acute motor and sensory axonal neuropathy) 
• Polyradiculopathy 
• Autonomic nervous system imbalance 
• Nerve palsy  
• ≥Grade 3 neurologic toxicities  
ADC Therapeutics  Camidanlumab tesirine (ADCT -301) 
Final ADCT -301-201 Clinical Protocol  Protocol Amendment 5 
Date of Protocol Amendment 5: 16 February 2022  Page 63 of 87 • ≥Grade 3 immune -mediated to xicities. Of note, rashes will not be considered as 
immune -mediated skin toxicities, since they are well  described toxicities of 
PBD- dimers ; with exception for Stevens -Johnson syndrome, toxic epidermal 
necrolysis, acute generalized exanthematous pustulosis, exfoliative dermatitis , and 
drug reaction with eosinophilia and systemic symptoms. 
• Autoimmune- mediated events ( such as , but not limited to, pneumonitis, hepatitis, 
colitis, endocrinopathies, type 1 diabetes mellitus, and nephritis/renal dysfunc tion) 
 
For all AESIs it is important to provide as much information as possible: e .g., time of onset  
(including changes in severity), duration of events, time to resolution, and relationship to 
camidanlumab tesirine. It is also important to specify if any AEs are autoimmune mediated.  
AESIs will be closely monitored and followed. 
8.2 Eliciting and Reporting Adverse Events/ Adverse Events of Special 
Interest/ Serious Adverse Events  
Patients will be instructed to contact the Investigator at any time after ICF signature if any symptoms develop. At each study visit, patients will be asked a non- leading question to elicit 
any medically related changes in their well -being. Patients may also report AEs voluntarily 
and they will be instructed to contact the Investigator between visits if any symptoms develop or worsen.  
All AEs will be reported starting when the patient provides written informed consent. 
Clinically  significant medical conditions present at the time of ICF signature will be reported 
as medical history. Clini cally significant medical conditions that start or worsen after ICF 
signature will be reported as AEs.  
All AE s, AESIs, and SAEs, regardless of relationship to study drug, will be reported from the 
time the patient signs the ICF until 30 days after the last dose of study drug; thereafter , only 
related SAEs will be reported  [For German S ites Only: thereafter, only SAEs will be  recorded 
(irrespective of the relationship to the study drug)] . The exception to this is patients who have 
responded to camidanlumab t esirine and undergo HSCT  (either autologous or allogeneic) after 
permanent discontinuation of camidanlumab tesirine treatment without any intervening anti -
cancer therapy  to treat relapsing disease (mobilization/conditioning treatment for HSCT is 
allowed ) or who have received CAR -T as the immediate subsequent anticancer therapy  
(mobilization/conditioning treatment for CAR -T is allowed). These patients will have the 
following safety information reported until 180 days post -HSCT /post- CAR-T regardless of 
relationship to camidanlumab tesirine:  
• ≥ Grade 3 AEs suggestive of hepatic toxicity, veno- occlusive disease/sinusoidal 
obstruction syndrome, graft -versus- host disease, infectious complications,  potentially 
immune -mediated adverse events,  prolonged cytopenia(s), and pulmonary toxicity 
• In addition, f or CAR- T therapy, any ≥ Grade 3 AEs of cytokine -release -syndrome and 
neurological toxicity  
ADC Therapeutics  Camidanlumab tesirine (ADCT -301) 
Final ADCT -301-201 Clinical Protocol  Protocol Amendment 5 
Date of Protocol Amendment 5: 16 February 2022  Page 64 of 87 • SAEs  
• Death  
 
Whenever possible, AEs should be reported as a diagnosis rather than individual signs and 
symptoms.  If no diagnosis is available or has been identified, then the primary symptom is 
reported. 
In general, the term ‘disease progression’ should not be used for reporting an AE/SAE. 
However, AEs/SAEs that are complications of disease progression should be reported.  
All AEs re ported or observed during the study will be recorded on the AE page of the 
eCRF.  Information to be collected will include event term, date of onset, assessment of severity 
(Section  8.3), seriousness ( Section  8.1), relationship to study drug ( Section  8.4), action taken 
with study drug, date of resolution of the event or ongoing (when no resolution by the end of the reporting period), any required treatment or evaluations, and outcome. 
New serious AESIs /SAEs and any recurrent episodes, progression, or complications of the 
original AESI/ SAE must be reported to the pharmacovigilance department of the Sponsor or 
delegate (e.g., contract research organization [CRO]) within 24  hours after the time site 
personnel first learn about the event. Reporting will occur through the electronic data capture 
(EDC) system.  
Any recurrence of GBS/polyradiculopathy, irrespective of the relationship to study drug, has to be reported to the Sponsor, including when the recurrence  occurs when the patient has 
already completed the study. The reporting of such events after the patient has completed the study will be captured via the Sponsor’s safety  database and therefore will not impact database 
lock. 
Non-serious AESIs must be entered in the EDC system and reported to the Sponsor or delegate 
(e.g., CRO) within 48 hours after the time site personnel first learn about the event. 
8.3 Assessment of Severity 
All AEs will be graded according to CTCAE v4.0. For events not included in the C TCAE 
criteria, the severity of the AE is graded on a scale of 1  to 5 as shown in Table  6.  
ADC Therapeutics  Camidanlumab tesirine (ADCT -301) 
Final ADCT -301-201 Clinical Protocol  Protocol Amendment 5 
Date of Protocol Amendment 5: 16 February 2022  Page 65 of 87 Table  6 Definition of Severity Grades for CTCAE  
Grade  Definition 
1 Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; 
intervention not indicated.  
2 Moderate; minimal, local, or noninvasive intervention indicated; limiting 
age-appropriate instrumental activi ties of daily living (ADL).a 
3 Severe or medically significant but not immediately life threatening; hospitalization 
or prolongation of hospitalization indicated; disabling; limiting self -care ADL.b 
4 Life-threatening consequences; urgent intervention indicated.  
5 Death related to adverse event.  
a. ADL refers to preparing meals,  shopping for groceries or clothes, using the  telephone, managing money, etc.  
b. Self-care ADL refers to bathing, dressing and undressing, feeding self, using the toilet, taking medications, 
and not bedridden.   
 
The AEs characterized as intermittent do not require documentation of onset and duration of 
each episode.  
8.4 Assessment of Causality  
The Investigator’s assessment of an AE’s relationship to study drug is an important part of 
safety reporting but is not a factor in determining whether an AE is reported. An AE will be assessed as related to study drug if there is a reasonable possibility of causal relationship with the use of the study drug. For SAEs, whenever possible, the Inve stigator should provide a 
rationale for the causality assessment.   
8.5 Regulatory Reporting  
Reporting of AEs to competent authorities  and Independent E thics Committees ( IECs) will be 
consistent with local laws, regulations, guidelines, and requests. 
8.6 Pregnancy Reporting  
Any pregnancy in a patient that occurs from signing the ICF up to 9.5 months after the last 
dose of study drug, whichever occurs last, must be reported using the Pregnancy Report Form. 
Any pregnancy in a partner of a male patient that occurs from  signing the ICF up to 6.5 months 
after last dose of study drug must be reported. Pregnancy must be reported within 24 hours 
after the site personnel first learn of the pregnancy. The pregnancy itself is not considered an AE. However,  the pregnancy must be  followed to determine outcome (including spontaneous 
miscarriage, elective termination, normal birth, or congenital abnormality) and status of mother and child, even if the patient discontinued from the study. Abortions (elective or spontaneous) must be r eported as an SAE.  
Any SAE occurring in association with a pregnancy that is brought to the Investigator’s attention after the patient has completed the study and considered by the Investigator as possibly related to the study drug must be promptly reporte d in the same manner.  
ADC Therapeutics  Camidanlumab tesirine (ADCT -301) 
Final ADCT -301-201 Clinical Protocol  Protocol Amendment 5 
Date of Protocol Amendment 5: 16 February 2022  Page 66 of 87 Once pregnancy is confirmed in a study participant, study drug will be discontinued; 
see Section  7.4.6 for additional information. 
8.7 Independent Data and Safety Monitoring Board 
An iDSMB will primarily  ensure the safety of patients enrolled in this study  by providing 
expertise and recommendation s for further study conduct and progress , which concern the 
continuation, modificatio n, or termination of the study. 
The iDSMB will be composed of at least one clinician with immun o-oncology expertise and a 
biostatistician. The board will meet  periodically  to review data , and as soon as possible upon 
occurrence of polyradiculopathy/GBS and possibly other relevant  ≥ Grade 3 autoimmune or 
neurologic toxicities  (see Section  4.3) or other concerning safety issues. 
Details regarding the iDSMB  responsibilities, authorities, and procedures  will be included in 
a separate iDSMB charter.  
ADC Therapeutics  Camidanlumab tesirine (ADCT -301) 
Final ADCT -301-201 Clinical Protocol  Protocol Amendment 5 
Date of Protocol Amendment 5: 16 February 2022  Page 67 of 87 9 Statistic al Considerations  
Full deta ils of the analysis plan, including a more technical and detailed elaboration of the 
statistical analyses, will be provided in the statistical analysis plan (SAP).  Results for the 
exploratory/correlative analyses may be reported separately.  
9.1 Sample Size Calculation  
This study uses a single -arm design to test for an improvement in response rate in the HL 
population. A sample size of 100 will provide a robust population for safety evaluation and 
adequate precision for observed ORR in the expected range. For  the test of efficacy, this study 
has > 98% power to distinguish between an active therapy with a 55% true response rate from 
a therapy with a response rate of 35% or less with a 1 -sided alpha of 0.025. 
9.2 Analysis Populations 
• All-Treated Population: All pati ents who receive at least 1 dose of camidanlumab tesirine. 
This population will be used in the primary analyses of efficacy and safety . 
• Per-Protocol Population: All patients in the all- treated population without important 
protocol deviations, which will be further described in detail in the SAP. 
• The PK Population: All  patients who receive study drug and have at least 1  pre- ( C1D1) 
and 1 postdose valid assessment.  
• The Pharmacodynamic Population : All patients who receive study drug and have at least 
1 valid pharmacodynamics/biomarker assessment . 
9.3 Interim Analysis  
No formal  interim analysis is planned.  
9.4 Final A nalysis  
For primary and key secondary endpoints analyses, a database snapshot will be taken when all patients who achieve PR or CR have a minimum of 12  months follow -up after initial 
documented response  (may be less for patients  undergoing HSCT) . All efficacy, safety, and 
PK endpoints will be analyzed and reported in the clinical study report (CSR).  
The exact binomial test will be used in the final analyses for the primary endpoint because of the practical consideration that accrual cannot be limited to exactly 100 patients ( ≤ 110 patients 
expected , see Table  7). 
ADC Therapeutics  Camidanlumab tesirine (ADCT -301) 
Final ADCT -301-201 Clinical Protocol  Protocol Amendment 5 
Date of Protocol Amendment 5: 16 February 2022  Page 68 of 87 Table  7 Number of R esponses N eeded to Have 95% CI L ow B ound of  ORR > 35% 
Total Patient s Enrolled  100 102 105 108 110 
Number of Responders  45 46 47 49 49 
Lower Bound of 95% E xact CI  35.03% 35.22% 35.05% 35.76% 35.07% 
 
Follow- up analyses will be performed when all the patients complete the study per protocol. 
The results will be reported in a CSR addendum. 
9.5 Demographics and Baseline C haracteristics  
Demographic s and B aseline characteristics,  such as  cancer history and medications history, 
will be summarized for the All -Treated  Population. 
9.6 Exposure to Treatments 
Exposure to study drug, prior , and concomitant medications will be summarized for the 
All-Treated analysis set by dose level. Dose interruptions, reductions, and relative dose 
intensity will also be summarized.  
9.7 Efficacy Analyses 
Primary efficacy analyses will be based on response as determined by central review. 
Response reported by Investigators will be used for sensitivity ana lyses.  
9.7.1 Overall Response Rate  
The ORR will be defined as the proportion of patients with a  best overall response  (BOR) of 
CR or PR. The overall response category will be derived based on response assessment performed on or before the start of subsequent ant i-cancer therapy. For the primary ORR 
analysis in the all -treated population, patients with a CR or PR will be counted as successes 
and all other patients (including those with missing response information) will be counted as failures.  
The percentage of OR R with its 95% confidence interval (CI) will be presented. In contrast to 
CR, PR, or PD, a BOR of SD  can only be made after the patient is on -study for a minimum of 
35 days after the first dose of study drug. Any tumor assessment indicating SD before this time period will be considered as a non- evaluable for BOR if no assessment after this time period 
is available.  
9.7.2 Duration of Response  
The DOR will be defined among responders (CR or PR) as the time from the earliest date of 
first response until the first da te of either disease progression or death due to any cause. 
The date of disease progression will be defined as the earliest date of disease progression based 
on central review. For patients who have not progressed or died at the time of the analysis, censo ring will be performed using the date of the last valid disease assessment  prior to 
ADC Therapeutics  Camidanlumab tesirine (ADCT -301) 
Final ADCT -301-201 Clinical Protocol  Protocol Amendment 5 
Date of Protocol Amendment 5: 16 February 2022  Page 69 of 87 initiation of a new anticancer therapy (including HSCT ). A sensitivity analysis of DOR is 
planned to be conducted in which the DOR for patients undergoing SCT is not censored at the 
last evaluable disease assessment prior to SCT.  The data will be analyzed by the Kaplan -Meier 
method. The  median DOR and 95% CI will be presented. DOR will be analyzed by response 
subgroup (CR, PR). Further details will be outlined in the SAP. 
9.7.3 Complete Response Rate  
Complete response r ate (CRR) will be defined as the proportion of patients with a best overall 
response of CR. The percentage of CRR with its 95% CI will be presented.  
9.7.4 Relapse -free Survival  
The RFS will be defined among CR patients as the time from the earliest date of first complete 
response until the first date of either disease relapse or death due to any cause. The date of 
disease progression will be defined as the earliest date of disease progression based on cent ral 
review. For patients who have not progressed or died at the time of the analysis, censoring will be performed using the date of the last valid disease assessment. The data will be analyzed by the Kaplan -Meier method. The median DOR and 95% CI will be presented. Further details 
will be outlined in the SAP.  
9.7.5 Progression-f ree Survival  
The PFS will be defined among all -treated patients as the time from first dose of study drug 
until the first date of either disease progression or death due to any cause. The date of disease progression will be defined as the earliest date of disease progression based on central review. For patients whose disease has not progressed at the time of the analysis, censoring will be 
performed using the date of the last valid disease assessment. The data will be analyzed by the 
Kaplan -Meier method. The  median PFS time and 95% CI will be presented. Further details 
will be outlined in the SAP.  
9.7.6 Overall Survival  
Median OS will be defined as the time from the fi rst dose of study drug until death due to any 
cause. For patients who have not died at the time of the analysis, censoring will be performed using the date the patient was last known to be alive. The data will be analyzed by the Kaplan -Meier method. The median OS and 95% CI will be presented. Further details will be 
outlined in the SAP. 
9.7.7 Patients Receiving Transplant  
The fraction of patients receiving HSCT following camidanlumab tesirine, and without any 
other anticancer therapy in between other than the therapies preparing for HSCT , will be 
summarized.  
9.8 Safety Analyses  
Safety analyses will be presented descriptively . 
ADC Therapeutics  Camidanlumab tesirine (ADCT -301) 
Final ADCT -301-201 Clinical Protocol  Protocol Amendment 5 
Date of Protocol Amendment 5: 16 February 2022  Page 70 of 87 9.8.1 Adverse Events 
The focus of AE  summarization will be on TEAEs. A TEAE  is defined as an AE  that occurs 
or worsens in the period extending from the first dose of study drug to 30  days after the last 
dose of study drug in this study or start of a new anticancer therapy/procedure, whichever 
comes earlier . 
All TEAEs will be summarized. Summary tabl es will be presented to show the number of 
patients reporting TEAEs by severity grade and corresponding percentages.  A patient who 
reports multiple TEAEs within the same Preferred Term (or System Organ Class) is counted 
only once for that Preferred Term (or System Organ Class) using the worst severity grade. 
Separate summaries will be prepared for TEAEs classified as severe or life threatening 
(Grade  3 or higher); study drug- related AEs; AEs leading to treatment interruption, 
modification, or discontinuation; AESIs; serious AEs; and death. 
9.8.2 Clinical Laboratory Results 
Clinical hematology, coagulation panel, biochemistry, and urinalysis data will be summarized 
at each scheduled assessment. Shi fts for clinical laboratory results that can be graded according 
to CTCAE v 4.0 will be summarized by CTCAE grade. Shifts for other numeric laboratory 
results will be by high/normal/low flag. Shifts for all other laboratory results will be by normal/abnorma l flag.  
Summaries by visit will include data from scheduled assessments, and all data will be reported according to the nominal visit date for which it was recorded. Unscheduled data will be included in “worst -case post  Baseline” summaries, which will capture a worst case across all 
scheduled and unscheduled visits after the first dose of study drug. Further details will be provided in the SAP. 
9.8.3 Additional Safety Assessments  
The results of scheduled assessments of vital signs, physical examinations, ECOG per formance 
status, and 12- lead ECGs will be summarized. All data will be reported according to the 
nominal visit date for which it was recorded (i.e., no visit windows will be applied). Unscheduled data will be included in “worst -case” summaries, which will capture a worst case 
across all scheduled and unscheduled visits after the first dose of study drug. All data will be 
listed. Further details will be provided in the SAP.  
9.9 Pharmacokinetic Analyses  
The PK profil e will include determination of  maximum concentration (C max), time to C max 
(Tmax), area under the concentration- time curve from time zero to the last quantifiable 
concentration (AUC last), area under the concentration- time curve from time zero to the end of 
the dosing interval (AUC tau), area under the concentration- time curve from time zero to infinity 
(AUC inf), apparent terminal elimination half -life ( Thalf), clearance (CL),  volume of distribution 
(Vss), and accumulation index (AI). 
ADC Therapeutics  Camidanlumab tesirine (ADCT -301) 
Final ADCT -301-201 Clinical Protocol  Protocol Amendment 5 
Date of Protocol Amendment 5: 16 February 2022  Page 72 of 87 Results from ADA testing will include tabular summarization for number/proportion of 
patients with positive predose ADA response, number of patients with postdose ADA response only, and number of patients with positive ADA response at any time.  The denominator will 
be the total number of patients tested for ADAs in the study.  For patients exhibiting a positive 
ADA, PK, safety and efficacy correlates will be assessed and reported.  
9.11 Exploratory Analyses 
Exploratory  analyses may be reported separately as an amendment to the CSR.  
ADC Therapeutics  Camidanlumab tesirine (ADCT -301) 
Final ADCT -301-201 Clinical Protocol  Protocol Amendment 5 
Date of Protocol Amendment 5: 16 February 2022  Page 73 of 87 10 Data Management and Quality Assurance 
The Investigator will maintain accurate  source documentation including patient medical 
records,  laboratory reports , ECG strips , and patient diaries. 
Investigative site qualified personnel will enter patient data into an EDC system . The analysis 
data sets will be a combination of these data and data from other sources.  
Clinical data management will be performed in acco rdance with applicable standards an d data 
cleaning procedures to ensure the integrity of the data ( e.g., removing errors and 
inconsistencies in the data). AE s will be coded using the Medical Dictionary for Regulatory 
Activities  (MedDRA) . Concomitant medication s will be coded using the world  health 
organization ( WHO ) Drug  Dictionary . 
After database lock, each study site will receive information about all of their site -specific 
eCRF data as entered into the EDC system for the study, including full discrepancy and audit 
history. Additionally, a copy of study data from all sites will be created and sent to the Sponsor 
for storage. The CRO will maintain a duplicate copy for its records. In all cases, patient initials 
will not be collected or transmitted to the Sponsor. 
For detail ed instruction on data entry  procedures and timelines , please refer to  the eCRF 
Completion Guidelines. 
ADC Therapeutics  Camidanlumab tesirine (ADCT -301) 
Final ADCT -301-201 Clinical Protocol  Protocol Amendment 5 
Date of Protocol Amendment 5: 16 February 2022  Page 74 of 87 11 Ethical , Regulatory, and Study Management Considerations 
11.1 Regulatory and Ethical Conduct of the Study  
The study will be performed in accordance with the ethical  principles that have their origin in 
the Declaration of Helsinki, International Council for Harmonisation (ICH ) Good Clinical 
Practice ( GCP ), and all applicable regulations.  
11.2 Independent Ethics Committee or Institutional Review Board 
Federal regulations an d ICH guidelines require that approval be obtained from an I nstitutional 
Review Board (IRB)/IEC before participation of human patients in research studies. 
Before  study onset, the protocol, informed consent, advertisements to be used for the 
recruitment of  study patients, and any other written information regarding this study intended 
to be provided to the patient must be approved by the IRB/IEC. Documentation of all IRB/IEC 
approvals will be maintained by the site and will be available for review by the Sponsor or its designee.  
All IRB/IEC approvals should be signed by the IRB/IEC chairman or designee and must identify the IRB/IEC name and address, the clinical protocol by title or protocol number or both, and the date approval or a favorable opinion was granted. 
The Investigator is responsible for obtaining continued review of the clinical research as 
specified by the IRB/IEC, at intervals not exceeding 1 year. The Investigator must supply the Sponsor or its designee with written documentation of continued review of the clinical research.  
11.3 Patient Information and Consent 
Informed consent in compliance with IRB/IEC and local regulations shall be obtained from 
each patient before performing any study procedures and will be documented with a signed IRB/IEC appro ved ICF . Before enrollment, each prospective patient will be given a full 
explanation of the study and be allowed to read the approved ICF. Once the Investigator is assured that the patient understands the implications of participating in the study, the patient 
will be asked to give consent to participate in the study and sign the ICF. The process for obtaining consent has to be documented at the institution. 
If the ICF is revised during the course of the study, all patients on-study , including those in 
follow-up, must sign the revised form, unless otherwise indicated by the IRB/ IEC  
(local or global, as applicable). In such cases , the reason for not re -consenting the patient 
should be documented. 
ADC Therapeutics  Camidanlumab tesirine (ADCT -301) 
Final ADCT -301-201 Clinical Protocol  Protocol Amendment 5 
Date of Protocol Amendment 5: 16 February 2022  Page 75 of 87 11.4 Confidentiality  
All laboratory specimens, evaluation forms, reports, and other records will be identified in a 
manner designed to maintain patient confidentiality. All records will be kept in a secure storage 
area with limited access. Clinical information will not be released without the written permission of the patient, except as necessary for monitoring and auditing by the Sponsor, its designee, regulatory authorities, or the IRB/IEC. 
The Investigator and other study staff  may not disclose or use for any purpose other than 
performance of the study any data, record, or other unpublished, confidential information 
disclosed to those individuals for the purpose of the study. Prior written agreement from the Sponsor or its designee must be obtained for the disclosure of any said confidential information to other parties. 
11.5 Financial Disclosure and Obligations  
Investigators are required to provide financial disclosure information to allow the Sponsor to submit the complete and accurate certification or disclosure statements as required under 21 CFR 54 and local regulations. In addition, the Investigator must promptly update this information if any relevant changes occur during the course of the investigation and for 1 year following the completion of the study. 
11.6 Study Conduct 
The Investigator will conduct all aspects of this study in accordance with the principles of the current version of ICH E6 as well as all national, state, and local laws and regulations. 
Study personnel involved in conducting this study will be qualified by education training and experience to pe rform their respective tasks.  Study information from this protocol will be 
posted on publicly available clinical study registers before enrollment of patients begins. 
11.7 Protocol Amendments 
Any change in the study plan requires a protocol amendment. All amendments to the protocol must be reviewed and approved following the same process as the original protocol before the amended protocol can be implemented. The Investigator will inform the governing IRB/IEC of all protocol amendments issued by the Sponsor in accordance with established IRB/IEC procedure. Only protocol amendments intended to eliminate an apparent immediate hazard to patient(s) may be implemented immediately, i.e. , without IRB/IEC approval, but the 
circumstances of the change must be documented and submitted to the IRB/IEC. 
ADC Therapeutics  Camidanlumab tesirine (ADCT -301) 
Final ADCT -301-201 Clinical Protocol  Protocol Amendment 5 
Date of Protocol Amendment 5: 16 February 2022  Page 76 of 87 11.8 Monitoring of the Study  
All aspects of the study will be carefully monitored by the Sponsor or designee for compliance 
with GCP and applicable government regulations. 
Investigators and institutions involved in the study will permit study- related monitoring, audits, 
IRB/IEC review, and regulatory inspections by providing direct access to all study records. 
In the event of an audit, the Investigator agrees to allow the Sponsor, representatives of the 
Sponsor, or a regulatory agency access to all study records. 
The Investigator should promptly notify the Sponsor and the CRO of any inspections scheduled 
by any regulatory authorities and promptly forward copies of any inspection reports received to the Sponsor. 
11.9 Records  Retention 
Essential documents should be retained for at least 15 years from the completion of the study (last patient last visit) or  until at least 2 years after the last approval of a ma rketing application 
in an ICH region or until there are no pending or contemplated marketing applications in an 
ICH region or at least 2 years have elapsed since the formal discontinuation of clinical development of the investigational study drug. However, these documents should be retained 
for a longer period if required by the applicable regulatory requirements or by an agreement with the Sponsor. It is the responsibility of the Sponsor to inform the Investigator/institution as to when these documents no longer need to be retained. 
11.10  Publications 
Following completion of the study, the results from the study may be reported publicly by making any oral public presentation and/or submitting or presenting a manuscript, abstract, or other materials relating to th e Study at scientific meetings and/or to a publisher, reviewer, or 
other outside person in scientific journals (“Publication”), provided, however, that Publication 
of the results from an individual  site shall not be made before the first multi -site Publication 
by Sponsor. The Sponsor shall coordinate the drafting, editing, authorship, and other activities related to study Publication and shall mutually agree with the Investigator(s) on the number, 
medium, forum , and timing for Publication. The Sponsor shall solicit input regarding contents 
of the Publication from all Investigators and in consultation with all sites. The Sponsor 
acknowledges the right of the Investigator(s) to publish the results of this study after the entire study has completed, but also reserves the right to a window to review the Publication for regulatory compliance as well as for protection of its intellectual property. In particular, the 
Sponsor may request to remove the Sponsor ’s confidential information and suspend 
Publication for a certain period of time to protect the Sponsor’s intellectual property interest, 
as further set forth in the Clinical Trial Agreement with the clinical study site(s) and Investigator(s).  
ADC Therapeutics  Camidanlumab tesirine (ADCT -301) 
Final ADCT -301-201 Clinical Protocol  Protocol Amendment 5 
Date of Protocol Amendment 5: 16 February 2022  Page 77 of 87 12 Reference Li st 
Adair JR, Howard PW, Hartley JA, Williams DG, Chester KA. Antibody- drug conjugates - a 
perfect synergy. Expert Opin Biol Ther  2012; 12(9):1191-1206. 
Alberti P, Beretta S, Piatti M, Karantzoulis A, Piatti ML, Santoro P, et al. Guillain -Barré 
syndrome rel ated to COVID- 19 infection. Neurol Neuroimmunol Neuroinflamm  2020; 
7(4):e741. 
Beck A, Goetsch L, Dumontet C, Corvaïa N. Strategies and challenges for the next generation 
of antibody-drug conjugates. Nat Rev Drug Discov  2017; 16(5):315-337. 
Brahmer  JR, Lacchetti  C, Schneider BJ , Atkins MB, Brassil KJ, Caterino JM,  et al. 
Management of immune -related adverse events in patients treated with immune checkpoint 
inhibitor therapy: American Society of Clinical Oncology clinical practice guideline. J Cli n 
Oncol 2018;  36(17):1714-1768. 
Cairo MS. Coiffier B, Reiter A, and Younes A, on behalf of the TLS Expert Panel.  
Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS  panel consensus.  
Br J Haem atol 2010; 149(4):578–586. 
Cerny JH, Yu H, Ramanathan M, Raffel GD, Walsh WV , Fortier N, et al. Expression of CD25 independently predicts early treatment failure of acute myeloid leukaemia (AML).  
Br J Haematol 2013; 160(2):262-266. 
Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. 
Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: The Lugano classification. J Clin Oncol  2014; 32(27):3059-3068. 
CIOMS Working Group. Drug- Induced Liver Injury (DILI): Current Status and Future 
Directions for Drug Development and the Post -Market Setting. Geneva, 2020. 
https://cioms.ch/wp-content/uploads/2020/06/CIOMS_DILI_Web_16Jun2020.pdf. 
Davies M and Duffield E M. Safety of checkpoint inhibitors for cancer treatment: strategies for 
patient monitoring and management of immune -mediated adverse events. Immunotargets Ther  
2017; (6):51-71. Fields  P, Wrench  D. Hodgkin lymphoma. Medicine  2017; 45(5):305-310 
https://www.medicinejournal.co.uk/article/S1357 -3039(17)30039- 7/abstract  
Flynn MJ and Hartley JA.  The emerging role of anti -CD25 directed therapies as both immune 
modulators and targeted agents in cancer. Br J Haematol  2017; 179(1):20-35. 
Fujiwara S, Muroi K, Tatara R, Matsuyama T, Ohmine K, Suzuki T, et al.  
Clinical features of d e novo CD25- positive follicular lymphoma.  
Leuk Lymphoma 2013a; V55(2):307-313. Fujiwara S, Muroi K, Hirata Y , Sato K, Matsuyama T, Ohmine K, et al.  
Clinical features of de novo CD25(+) diffuse large B -cell lymphoma.  
Hematology 2013b; 18(1):14 -19. 
ADC Therapeutics  Camidanlumab tesirine (ADCT -301) 
Final ADCT -301-201 Clinical Protocol  Protocol Amendment 5 
Date of Protocol Amendment 5: 16 February 2022  Page 78 of 87 Geng  H, Brennan S, Milne TA, Chen WY , Li Y , Hurtz C, et al.  
Integrative epigenomic analysis identifies biomarkers and therapeutic targets in adult B -acute 
lymphoblastic leukemia. Cancer Discov 2012; 2(11):1004-1023. 
Glimelius I and Diepstra A. Novel treatment concepts in Hodgkin lymphoma.  
J Intern Med  2017; 281(3):247-260. 
Gu Y , Menzies AM, Long GV , Fernando SL, Herkes G. Immune mediated neuropathy 
following checkpoint immunotherapy. J Clin Neurosci 2017; 45:14-17. 
Hartley JA. The development of pyrrolobenzodiazepines as antitumour agents. Expert Opin Investig Drugs  2011; 20(6):733-744. 
Hlubocky FJ, Webster K, Cashy J, et al. The development and validation of a measure of 
health -related quality of life for non-hodgkin’ s lymphoma: the functional assessment of can cer 
therapy −lymphoma (FACT -Lym). Lymphoma 2013; 2013:1-9. 
LeMaistre CF, Saleh MN, Kuzel TM, Foss F, Platanias LC, Schwartz G, et al. Phase I trial of a ligand fusion- protein (DAB389IL -2) in lymphomas expressing the receptor for interleukin -
2. Blood 1998; 91(2):399-405. 
Lim KH, Tefferi A, Lasho TA, Finke C, Patna ik M, Butterfield JH, et al. Systemic mastocytosis 
in 342 consecutive adults: survival studies and prognostic factors. 
Blood 2009; 113(23): 5727-5736. 
Mehta- Shah N  and Bartlett NL. Management  of relapsed/refractory classical Hodgkin 
lymphoma in transplant- ineligible patients.  Blood  2018; 131(15):1698-1703. 
Mottok A and Steidl C. Biology of classical Hodgkin lymphoma: implications for prognosis 
and novel therapies. Blood  2018; 131(15):1654-1665. 
Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group.  
Am J Clin Oncol  1982; 5(6):649-655. 
Olsen E, Duvic M, Frankel A, Kim Y , Martin A, V onderheid E, et al. Pivotal phase III trial of 2 dose levels of denileukin diftitox for the treatment of cutaneous T -cell lymphoma.  
J Clin Oncol  2001; 19(2):376-388. 
Prince HM, Duvic M, Martin A, Sterry W, Assaf C, Sun Y , et al. Phase III placebo -controlled 
trial of denileukin diftitox for patients with cutaneous T -cell lymphoma.  
J Clin Oncol  2010; 28(11):1870-1877. 
Schnell R, Vitetta E, Schindler J, Barth S, Winkler U, Borchmann P, et al. Clinical trials with 
an anti -CD25 ricin A -chain experimental and immunotoxin (RFT5- SMPT -dgA) in Hodgkin's 
lymphoma. Leuk Lymphoma 1998; 30(5-6):525-537. 
Sejvar JJ, Kohl KS, Gidudu J, Amato A, Bakshi N, Baxter R, et al. Guillain- Barre syndrome 
and Fisher syndrome: case definitions and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine  2011; 29(3):599-612. 
Shao H, Calvo KR, Gronborg M, Tembhare PR, Kreitman RJ, Stetler -Stevenson M,et al . 
Distinguishing hairy cell leukemia variant from hairy cell leukemia: development and validation of diagnostic criteria. Leuk Res 2013; 37(4): 401-409. 
ADC Therapeutics  Camidanlumab tesirine (ADCT -301) 
Final ADCT -301-201 Clinical Protocol  Protocol Amendment 5 
Date of Protocol Amendment 5: 16 February 2022  Page 79 of 87 Shvidel L, Braester A, Bairey O, Rahimi -Levene N, Herishanu Y , Tadmor T , et al.  
Cell surface expression of CD25 antigen (surface IL -2 receptor alpha- chain) is not a prognostic 
marker in chronic lymphocytic leukemia: results o f a retrospective study of 281 patients.  
Ann Hematol  2012; 91(10):1597-1602. 
Smith TJ, Khatcheressian J, Lyman GH, Ozer H, Armitage JO, Balducci L, et al. 2006 update 
of recommendations for the use of white blood cell growth factors: An Evidence -Based 
Clinical Practice Guideline. J Clin Oncol 2006; 24(19):3187-3205. 
Strauchen JA, Breakstone BA. IL -2 receptor expression in human lymphoid lesions. 
Immunohistochemical study of 166 cases. Am J Pathol 1987; 126(3):506-512. Toscano  G, Palmerini F, Ravaglia S, Ruiz L, Invernizzi P, Cuzzoni MG, et al. Guillain –Barré 
Syndrome Associated with SARS- CoV-2. N Engl J Med 2020; 382:2574-2576. 
Waldmann TA, White JD, Carrasquillo JA, Reynolds JC, Paik CH, Gansow OA, et al. 
Radioimmunotherapy of interleukin -2R alpha -expressing adult T -cell leukemia with 
Yttrium -90-labeled anti -Tac. Blood 1995; 86(11):4063-4075. 
Zhao  H, Shen  D, Zhou H , Liu  J, Chen S (2020) . Guillain -Barré syndrome associated with 
SARS -CoV-2 infection: causality or coincidence? Lancet Neurol  2020; 19(5):383- 384. 
ADC Therapeutics  Camidanlumab tesirine (ADCT -301) 
Final ADCT -301-201 Clinical Protocol  Protocol Amendment 5 
Date of Protocol Amendment 5: 16 February 2022  Page 80 of 87 13 Appendices 
13.1 Appendix: Eastern Cooperative Oncology Group Performance Status 
Performance status will be assessed using the ECOG performance status grades as indicated 
below: 
Grade  Definition 
0 Fully active, able to carry on all pre -disease performance without restriction  
1 Restricted in physically strenuous activity but ambulatory and able to carry out work of 
a light or sedentary nature, e.g., light house work, office work  
2 Ambulatory and capable of all self-care but unable to carry out any work activities; 
up and about more than 50% of waking hours  
3 Capable of only limited self -care; confined to bed or chair more than 50% of waking 
hours  
4 Completely disabled ; cannot carry on any self-care; totally confined to bed or chair  
5 Dead  
Reference:  Oken , 1982 
 
ADC Therapeutics  Camidanlumab tesirine (ADCT -301) 
Final ADCT -301-201 Clinical Protocol  Protocol Amendment 5 
Date of Protocol Amendment 5: 16 February 2022  Page 81 of 87 13.2 Appendix: Clinical C ase Definitions: Level 1 of D iagnostic Certainty 
for Guillain- Barré Syndrome  (GBS)  
• Bilateral AND flaccid weakness of the limbs1, 2, 3 
AND  
• Decreased or absent deep tendon reflexes in weak limbs4 
AND  
• Monophasic illness pattern5 AND interval between onset and nadir of weakness 
between 12 h and 28 days AND subsequent clinical plateau6 
AND  
• Electrophysiologic findings consistent with GBS7 
AND  
• Cytoalbuminologic dissociation (i.e. , elevation of CSF protein level above laboratory 
normal value AND CSF total white cell count < 50 cells/µL)8 
AND  
• Absence of an identified alternative diagnosis for weakness9 
Reference:  Sejvar , 2011 
1. Weakness is usually, but not always, symmetric in nature, and usually has a pattern of progression from 
legs to arms (ascending). However, other patterns of progression may occur (e.g., beginning in the arms). 
The degree of weakness can range from mild to moderate to severe, i.e., com plete paralysis.  
2. Respiratory or cranial nerve- innervated muscles may also be involved.  
3. It is important that strength be assessed in a manner that takes into account subject age, sex, and level of functioning. 
4. Decreased or absent tendon reflexes may also be seen in limbs without weakness. However, to meet case 
definition criteria, decreased or absent tendon reflexes must be observed in weak limbs.  
5. Fluctuations in level of weakness, before reaching nadir, or during the plateau or improvement phases, occur in some cases, usually associated with the use of disease- modifying therapies. Such fluctuations 
usually occur within the first 9 weeks after onset and are followed by eventual improvement.  
6. The eventual outcome is either stabilization at nadir OR subsequent i mprovement OR death.  
7. Electrophysiologic patterns consistent with polyneuropathy of the types described for GBS. 
Electrophysiologic studies performed sooner than 7 days after weakness onset may be normal and should 
thus be repeated at a later time if possible, and “normal” studies may occur in otherwise typical cases of GBS. However, cases with persistently “normal” studies will not meet Level 1 criteria.  
8. CSF (cerebrospinal fluid) protein concentrations should be elevated above what is considered norma l 
reference values for the testing laboratory. CSF may be “normal” in otherwise typical cases of GBS; this is particularly true within the first week of illness. However, cases with persistently “normal” CSF, or CSF 
with ≥ 50 WBC, will not meet Level 1 cri teria.  
9. If an alternative diagnosis explaining flaccid weakness/paralysis is present a diagnosis of Guillain –Barré 
syndrome is excluded. However, in many, if not most cases, a comprehensive documentation of testing 
for various other etiologies will either b e incomplete or unavailable. These case definitions are provided 
to give guidance in the absence of detailed information on investigations for alternative etiologies of 
flaccid paralysis.  
 
ADC Therapeutics  Camidanlumab tesirine (ADCT -301) 
Final ADCT -301-201 Clinical Protocol  Protocol Amendment 5 
Date of Protocol Amendment 5: 16 February 2022  Page 82 of 87 13.3 Appendix: Guillain –Barré Syndrome Disability S cale 
Score  Description  
0 Healthy  
1 Minor symptoms or signs of neuropathy but capable of manual work/capable of 
running  
2 Able to walk without support of a stick (5  m across an open space) but incapable of 
manual work/running  
3 Able to walk with a stick, appliance, or support (5 m across an open space)  
4 Confined to bed or chair bound  
5 Requiring assisted ventilation (for any part of the day or night)  
6 Death  
Reference:  Sejvar , 2011 
ADC Therapeutics  Camidanlumab tesirine (ADCT -301) 
Final ADCT -301-201 Clinical Protocol  Protocol Amendment 5 
Date of Protocol Amendment 5: 16 February 2022  Page 83 of 87 13.4 Appendix: Response Assessment of Hodgkin and Non-Hodgkin 
Lymphoma (Lugano Classification)  
Response/Site  PET- CT-Based Response  CT-Based Response  
Complete Complete metabolic response  Complete radiologic response   
(all of the following) 
Lymph nodes and 
extralymphatic sites  • Score 1, 2, or 3* with or without a residual 
mass on 5PS** 
Note: Uptake may be greater than normal 
mediastinum and/or liver in Waldeyer’s ring or extranodal sites with high physiologic 
uptake or with activation within spleen or 
marrow (e.g., with chemotherapy or myeloid 
colony-stim ulating factors). In this 
circumstance, complete metabolic response 
may be inferred if uptake at sites of initial 
involvement is no greater than surrounding 
normal tissue even if the tissue has high 
physiologic uptake  • Target nodes/nodal masses must regress to 
≤ 1.5 cm in LD  
• No extralymphatic sites of disease  
Nonmeasured lesion • Not applicable  • Absent  
Organ enlargement  • Not applicable  • Regress to normal  
New lesions  • None • None 
Bone marrow  • No evidence of FDG -avid disease in 
marrow • Normal by morphology; if indeterminate, 
IHC negative  
Partial Partial metabolic response  Partial remission   
(all of the following) 
Lymph nodes and extralymphatic sites  • Score 4 or 5** with reduced uptake 
compared with baseline and residual 
mass(es) of any size.  
• At interim, these findings suggest 
responding disease.  
• At end of treatment, these findings indicate 
residual disease.  • ≥ 50% decrease in SPD of up to 6 target 
measurable nodes and extranodal sites 
• When a lesion is too small to measure on 
CT, assign 5 mm × 5mm as the default 
value. 
• When no longer visible, 0 × 0 mm  
• For a node > 5 mm × 5 mm, but smaller 
than normal, use actual measurement for calculation  
Nonmeasured lesion • Not applicable  • Absent/normal, regressed, but no increase  
Organ enlargement  • Not applicable  • Spleen must have regressed by > 50% in 
length beyond normal  
New lesions  • None • None 
ADC Therapeutics  Camidanlumab tesirine (ADCT -301) 
Final ADCT -301-201 Clinical Protocol  Protocol Amendment 5 
Date of Protocol Amendment 5: 16 February 2022  Page 84 of 87 Response/Site  PET- CT-Based Response  CT-Based Response  
Bone marrow  • Residual uptake higher than uptake in 
normal marrow but reduced compared with 
baseline (diffuse uptake compatible with 
reactive changes from chemotherapy 
allowed). If there are persistent focal 
changes in the marrow in the context of a nodal response, consideration should be 
given to further evaluation with MRI or 
biopsy or an interval scan  • Not applicable  
No response or stable 
disease  No metabolic response  
 Stable disease  
Target nodes/nodal 
masses, extranodal lesions • Score 4 or 5 with no significant change in 
FDG up take from baseline at interim or 
end of treatment  • < 50% decrease from baseline in SPD of 
up to 6 dominant, measurable nodes and 
extranodal sites; no criteria for progressive 
disease are met  
Nonmeasured lesions  • Not applicable  • No increase consistent with progression 
Organ enlargement  • Not applicable  • No increase consistent with progression 
New lesions  • None • None 
Bone marrow  • No change from baseline  • Not applicable  
Progressive disease Progressive metabolic disease  Progressive disease  
(requires at least 1 of the following) 
Individual target 
nodes/nodal masses  • Score 4 or 5 with an increase in intensity of 
uptake from baseline and/or  • PPD progression  
Extranodal lesions  • New FDG-avid foci consistent with 
lymphoma at interim or end of treatment assessment  An individual node/lesion must be abnormal 
with:  
• LDi > 1.5 cm and  
• Increase by ≥  50% from PPD nadir and  
• An increase in LDi or SDi from nadir  
0.5 cm for lesions ≤  2 cm  
1.0 cm for lesions > 2 cm  
• In the setting of splenomegaly, the splenic 
length must increase by > 50% of the 
extent of its prior increase beyond baseline 
(e.g., a 15 -cm spleen must increase to > 16 
cm). If no prior splenomegaly, must increase by at least 2 cm from baseline  
• New or recurrent splenomegaly 
Nonmeasured lesions  • None • New or clear progression of preexisting 
nonmeasured lesions  
ADC Therapeutics  Camidanlumab tesirine (ADCT -301) 
Final ADCT -301-201 Clinical Protocol  Protocol Amendment 5 
Date of Protocol Amendment 5: 16 February 2022  Page 85 of 87 Response/Site  PET- CT-Based Response  CT-Based Response  
New lesions  • New FDG-avid foci consistent with 
lymphoma rather than another etiology 
(e.g., infection, inflammation). If uncertain 
regarding etiology of new lesions, biopsy 
or interval scan may be considered • Regrowth of previously resolved lesions  
• A new node > 1.5 cm in any axis  
• A new extranodal site > 1.0 cm in any axis; 
if < 1.0 cm in any axis, its presence must be unequivocal and must be attributable to lymphoma  
• Assessable disease of any size 
unequivocally attributable to lymphoma  
Bone marrow  • New or recurrent FDG-avid foci  • New or recurrent involvement  
Abbreviations: 5PS, 5 -point scale; CT, computed tomography; FDG, fluorodeoxyglucose; IHC, immunohistochemistry; 
LDi, longest transverse diameter of a lesion; MRI, magnetic resonance imaging; PET, positron emission tomography; PPD, 
cross product of the LDi and perpendicular diameter; SDi, shortest axis perpendicular to the LDi; SPD, sum of the product 
of the perpendicular diameters for multiple lesions.  
* A score of 3 in many patients indicates a good prognosis with standard treatment, especially if at the time of an interim 
scan. However, in trials involving PET where de -escalation is investigated, it may be preferable to consider a score of 3 as 
inadequ ate response (to avoid undertreatment). Measured dominant lesions: Up to six of the largest dominant nodes, nodal 
masses, and extranodal lesions selected to be clearly measurable in 2 diameters. Nodes should preferably be from disparate 
regions of the body  and should include, where applicable, mediastinal and retroperitoneal areas. Non-nodal lesions include 
those in solid organs (e.g., liver, spleen, kidneys, lungs), GI involvement, cutaneous lesions, or those noted on palpation. 
Nonmeasured lesions: Any di sease not selected as measured, dominant disease and truly assessable disease should be 
considered not measured. These sites include any nodes, nodal masses, and extranodal sites not selected as dominant or measurable or that do not meet the requirements for measurability but are still considered abnormal, as well as truly 
assessable disease, which is any site of suspected disease that would be difficult to follow quantitatively with measurement,  
including pleural effusions, ascites, bone lesions, leptomeningeal disease, abdominal masses, and other lesions that cannot 
be confirmed and followed by imaging. In Waldeyer’s ring or in extranodal sites (e.g., GI tract, liver, bone marrow), FDG 
uptake may be greater than in the mediastinum with complete metabolic r esponse, but should be no higher than surrounding 
normal physiologic uptake (e.g., with marrow activation as a result of chemotherapy or myeloid growth factors).  
** PET 5PS: 1, no uptake above background; 2, uptake ≤  mediastinum; 3, uptake >  mediastinum b ut ≤  liver; 
4, uptake moderately > liver; 5, uptake markedly higher than liver and/or new lesions; X, new areas of uptake unlikely to 
be related to lymphoma.  
Reference:  Cheson , 2014 
 
ADC Therapeutics  Camidanlumab tesirine (ADCT -301) 
Final ADCT -301-201 Clinical Protocol  Protocol Amendment 5 
Date of Protocol Amendment 5: 16 February 2022  Page 86 of 87 13.5 Appendix: Management of Specific Autoimmune T oxicities: 
Hyperthyroidism, Hypothyroidism, and Hepatitis  
Adverse Event Grade  Camidanlumab Tesirine Management Guideline  
Hyperthyroidism  1 No dose adjustment is required .  
Close follow -up (at least weekly; by phone if stable) and 
monitoring of TSH , reflex FT4 and/or FT3  (as applicable), 
every 2-3 weeks, until it is clear whether there will be 
persistent hyperthyroidism  (>6 weeks)  or hypothyroidism.  
 2 Consider endocrine consultation.  
Dose delay is at  the Investigator’s discretion.  Rechallenge 
without dose adjustment is permitted.  
β-blocker ( e.g., atenolol) for symptomatic relief , hydration , 
and supportive care may be needed. 
For persistent hyperthyroidism or clinical suspicion (e. g., 
ophthalmopathy or thyroid bruit) , work -up for Graves disease 
and consider thionamide . 
 3/4 Endocrine consultation is indicated.  
Hold camidanlumab tesirine until improvement to ≤ Grade 1 
or Baseline with appropriate therapy.  Rechallenge is then 
permitted as per General Guidelines for Dose Modification  
(Section  6.4.1 ). 
Give β-blocker (e .g., atenolol) for symptomatic relief.  
For severe symptoms or concern for thyroid storm, hospitalize 
patient and initiate prednisone 1- 2 mg/kg/day or equivalent 
tapered over 1 -2 weeks; consider also use of saturated 
solutions of potassium iodide  or thionam ide. 
Hypothyroidism  1 Asymptomatic; TSH  generally  <10 mIU/L. 
No dose adjustment is required .  
Close follow -up (at least weekly; by phone if stable) and 
monitoring of TSH , FT4/FT3  (as applicable) every 4 -6 weeks.  
 2 TSH generally persists >10 mIU/L.  
Consider endocrine consultation.  
Dose delay is at the Investigator’s discretion.  Rechallenge 
without dose adjustment  is permitted . 
Give thyroid hormone supplementation in symptomatic 
patients with any degree of TSH elevation or in asymptomatic patients with TSH levels that persist >10 mIU/L.  
Monitor TSH , FT4/FT3  (as applicable) every 6 -8 weeks while 
titrating hormone replacement to normal TSH.  Thereafter, 
monitor TSH , FT4  and/or FT3 (as applicable)  every 6 weeks 
during camidanlumab tesirine treatment or as needed for 
symptoms to ensure appropri ate hormone replacement; repeat 
testing annually or as indicated by symptoms once stable . 
ADC Therapeutics  Camidanlumab tesirine (ADCT -301) 
Final ADCT -301-201 Clinical Protocol  Protocol Amendment 5 
Date of Protocol Amendment 5: 16 February 2022  Page 87 of 87 Adverse Event Grade  Camidanlumab Tesirine Management Guideline  
 3/4 Endocrine consultation is indicated.  
Hold camidanlumab tesirine until improvement to ≤ Grade 1 
or Baseline, or control  with appropriate supplementation.  
Rechallenge is then permitted as per General Guidelines for 
Dose Modification ( Section  6.4.1). 
May admit for IV therapy if signs of myxedema (bradycardia, hypothermia)  
Provide t hyroid supplementation and reassessment as in Grade 
2. 
Hepatitis  1/2 Asymptomatic LFT elevations and Hy’s law should be 
managed per guidance s given in the S ection  6.4.2. 
Consider work-up for other causes of elevated liver enzymes 
(CIOMS Working Group consensus, 2020): e. g., viral 
hepatitis, alcohol history, iron study, thromboembolic event, 
liver ultrasound, cross -sectional imaging for potential liver 
metastasis. A ntinuclear antibodies, antismooth muscle 
antibodies, and/or antineutrophil cytoplasmic antibodies  
testing can be considered if suspicion for primary 
autoimmune hepatitis.  
 3 Consider hepatology consult and biopsy. Work-up for 
alternative causes as in Grade 2.  
Permanently discontinue camidanlumab tesirine. 
Closely monitor chemistries  (every 1 -2 days) . Consider 
inpatient monitoring for patients with AST/ALT > 8 x ULN 
and/or elevated total bilirubin > 3 x ULN.  
Immediately start corticosteroid 1-2 mg/kg 
methylprednisolone or equivalent; seek hepatology 
consultation . If corticosteroid refractory or no im provement 
after 3 days, consider additional treatments such as mycophenolate mofetil or azathioprine . 
Corticosteroid tapering can be attempted around 4-6 weeks; re-escalate if needed.  
 4 Consider hepatology consult and biopsy. Work-up for 
alternative causes as in Grade 2.  
Permanently discontinue camidanlumab tesirine. 
Monitor chemistries daily, consider inpatient monitoring.  
Administer 2  mg/kg/day methylprednisolone or equivalent , 
avoid use of infliximab. 
Corticosteroid tapering can be attempted around  4-6 weeks 
when symptoms improve to ≤ Grade 1 or Baseline; re -
escalate if needed.  
 